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1 Introduction  
Hepatitis E is an emerging infectious disease distributed worldwide which affects 
humans. The causative agent Hepatitis E virus (HEV) also occurs in animals such as 
domestic swine and wild boar. HEV was first associated with acute hepatitis in humans 
on basis of clinical and epidemiological observations. The disease is self-limiting in the 
majority of the patients, however, high morbidity and mortality rates have been 
described in pregnant women. In contrast no clinical disease has been associated with 
HEV in animals.  
The objectives of this work were: 
 Detection of HEV in different animal populations;  
 Study of the genetic variability of HEV;  
 Expression of the capsid protein;  
 Cultivation of HEV in cell lines and primary cells 
 
 
2 Literature review 
2.1 Taxonomy and phylogeny of hepeviridae 
2.1.1 Taxonomy and phylogeny 
Due to clinical and epidemiological characteristics Hepatitis E virus (HEV) was 
initially thought to belong to the same family as Hepatitis A virus (HAV), namely the 
Picornaviridae (Sreenivasan et al., 1984a). According to morphological features and 
similarities to Noroviruses with regard to genome organization (Bradley et al., 1988), 
HEV was then repositioned as a member of the Caliciviridae in a separate genus 
Hepevirus. Based on molecular analyses HEV was later placed as a single species of 
the family Hepeviridae, genus Hepevirus (Emerson et al., 2005; Meng et al., 2011). In 
the meantime three distinct avian hepatitis E viruses (avian HEV) were considered as 
genotypes within an unassigned species in the family Hepeviridae (Meng et al., 2011). 
The recently reported rat hepatitis E virus is a related virus which may represent a new 
genotype (Meng et al., 2011). 
Another potential member of the family recently identified in cutthroat trout shows 
similarities to HEV in genome organization and size of 7269 nt. Phylogenetic analyses 
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suggested that the cutthroat trout virus (CTV) is also a new member of the family 
Hepeviridae (Batts et al., 2011). 
According to the commonly accepted classification HEV found in mammals can 
be grouped into four major genotypes (1-4) with 24 proposed subtypes (Lu et al., 2006). 
This classification was confirmed by the ninth ICTV report which lists the four genotypes 
Burma (1), Mexico (2), Meng (3) and T1 (4) within the HEV species (Figure 1) (Meng et 
al., 2011).  
The criterion adopted for definition of genotypes is a divergence of nucleotide 
sequences in the ORF 2 region of more than 20 %, similar to the criteria used for 
Noroviruses (Worm et al., 2002). Genotypes 1 and 2 were found only in humans. 
Genotypes 3 and 4 have been reported in humans and in different animal species and 
are connected to zoonotic cases (Panda et al., 2007; Pavio et al., 2010). 
 
Figure 1: Phylogenetic tree based on complete capsid sequences showing the four major genotypes, the new 
wild boar genotypes and the rat and chicken viruses. Tree was calculated by the neighbor-joining methods. 
Branches are proportional to the genetic distances. 
Subtype classification is controversial and not accepted by all researchers in the 
field. For instance, there are a number of publications including partial and complete 
genomic sequences of HEV with no differentiation into subtypes (Sonoda et al., 2004; 
Takahashi et al., 2003; Tei et al., 2003; Wibawa et al., 2004). Based on this mismatch, a 
part of this thesis deals with the classification of HEV (Oliveira-Filho et al., 2013). 
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2.2 Early history 
The first epidemiological study about hepatitis E came from India in the early 
Fifties. The infectious acute hepatitis outbreak in Delhi was extensively described. In the 
peak of the outbreak the incidence was almost 190 cases per day. During more than 6 
weeks about 29,300 cases were reported; it has been estimated that approximately 68 
% of the population of Delhi was infected (Viswanathan, 1957). Without knowing the 
infectious agent a very detailed study was performed; some epidemiological data 
differed from hepatitis caused by HAV. The fatality-rate showed that the pathogen was 
of low virulence. However, when “infectious hepatitis” occurred during pregnancy there 
were reports of complications such as still-birth, neonatal death and a high case-fatality 
ratio. The study pointed to water borne infection due to sewage contamination of the 
Jumna River, the main water source. Nevertheless the unusual pathogen was not 
identified (Naidu and Viswanathan, 1957). More than 15 years after the outbreak a 
group of researchers analyzed patient samples from the Delhi outbreak 1955-56 and two 
more infectious hepatitis outbreaks in India (Ahmedabad 1975-76 and Pune 1978-79). 
No evidence for infection with either HAV or HBV was found and it was suggested that 
an unrecognized agent had been responsible for the outbreaks (Wong et al., 1980). 
Previous studies suggested the presence of unknown non-A and non-B viral agent(s) 
linked to hepatitis in different countries and designated non-A and non-B hepatitis 
(Francis and Maynard, 1979; Stakhanova et al., 1979). The unknown agent was named 
“enterically transmitted non-A and non-B hepatitis” (ET-NANBH) (Jameel, 1999; 
Sreenivasan et al., 1984a). 
In 1983 a scientist infected himself ingesting fecal suspension from an ET-
NANBH patient. Spherical 27 to 30 nanometers virus-like particles (VLP) were observed 
in his feces and characterized using immune electron microscopy (IEM). The volunteer 
had previously been exposed to HAV and had no antibodies against HBV, but 
developed antibodies against the VLPs recovered in his feces. Afterwards cynomologus 
monkeys were inoculated with the virus-containing stool and hepatitis was confirmed by 
liver enzymatic profile, specific antibody response and excretion of VLPs (Balayan et al., 
1983). 
Later the ET-NANBH virus from a Burmese (Myanmar) patient was inoculated in 
cynomologus monkeys and HEV cDNA was isolated for the first time. In the same study 
it was also demonstrated that the viral genome had a plus strand RNA genome and was 
polyadenylated; the name hepatitis E virus (HEV) was proposed (Reyes et al., 1990; 
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Zuckerman, 1990). Afterwards the first full-length HEV genome was cloned and 
sequenced (Tam et al., 1991) and the structural proteins expressed, which allowed the 
development of serological diagnostic tests (He et al., 1995). Since then the number of 
reports of HEV in the human population has increased progressively showing that HEV 
was present in different continents and countries such as Pakistan (Tsarev et al., 1992), 
Mexico (Huang et al., 1992) and China (Aye et al., 1992; Yin et al., 1994). 
2.3 Morphology and molecular biology of HEV 
2.3.1 Morphology and genome organization  
HEV virions are non-enveloped spherical particles with a size of 27 to 32 nm in 
diameter. They possess a positive strand RNA genome with a size of approximately 7.2 
kb with three partly overlapping open reading frames (ORFs), a capped 5’ end and 
polyadenylated 3’ end  (Mushahwar, 2008). The genome organization is the same for 
genotypes 1, 2 and 3 and only differs regarding the position of ORF3 in genotype 4  (Fig 
2A and 2B) (Panda et al., 2007). In addition subgenomic viral RNA is also present (Graff 
et al., 2006).  
The 5’ end of the genome contains a short non-coding region (NCR) with 26 to 28 
nucleotides in length. ORF1 has a size of approximately 5.1 kb. This region encodes a 
polyprotein which is cleaved into the viral nonstructural proteins as methyltransferase, 
papain-like cysteine protease, helicase and RNA dependent RNA polymerase (RdRp); 
these enzymes are involved in viral replication, transcription and polyprotein cleavage 
(Kaur et al., 1992; Koonin et al., 1992; Reyes et al., 1990). 
ORF 2 encodes the structural capsid protein and has a size of approximately 
1983 nt for members of the genotypes 1, 2 and 3 and 2025 nt for members of genotype 
4. This protein is highly immunogenic and is responsible for the functions such as 
assembly and host interaction. It has a high nucleotide heterogeneity and has been 
subject of both diagnostic tests and vaccine development (Engle et al., 2002; Koff, 2007; 
Panda et al., 2007; Tsarev et al., 1997; Zhang et al., 2001b). 
ORF 3 has a size of 369 nt and encodes a small phosphorylated protein which 
binds to the hepatocellular cytoskeleton and forms a complex together with the capsid 
protein. Other possible ORF 3 functions are related to the regulation of cellular signs 
(Jiménez de Oya et al., 2007; Khuroo, 2008; Panda et al., 2007). 
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Genotypes 1,2 and 3 
 
Figure 2: Genome organization of GT 1-3 (A) and GT 4 and HEV like viruses from wild boar, rat and Cutthroat 
trout virus (B). Scale from 1 to 7 shows genome size in kilo bases (Kb). 
2.3.2 Genome replication 
Due to the lack of an efficient cell culture system or animal model the 
mechanisms of HEV replication are not well known. A replication model has been 
proposed based on analogy to other single stranded RNA viruses and some knowledge 
of HEV (Fig. 3)(Ahmad et al., 2011). It is believed that HEV particle uptake occurs by 
receptor-mediated endocytosis using a not yet identified receptor at the cell surface. 
After uncoating, RNA is translated into the non-structural polyprotein by host ribosomes; 
it is assumed that the papain-like protease cleaves the ORF 1 encoded polyprotein. The 
RdRp replicates (alone or with aid of cellular proteins) the positive RNA into negative 
RNA strands (Agrawal et al., 2001), which will serve as template for synthesis of the 
positive sense RNA strand by the viral RNA polymerase. In parallel the subgenomic 
RNA is translated by the structural proteins in the ORF 2 and ORF 3. The capsid protein 
packages the genome probably with the aid of the cytoskeleton phosphoprotein (ORF 3) 
and the virions are assembled and released by a mechanism not yet identified.  
Three potential N-glycosylation sites have been identified within the capsid 
protein sequence (Asn137, Asn310 and Asn562), however the ORF 2 protein is 
probably not glycosylated (Mori and Matsuura, 2011). 
A 
B 
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Figure 3: Proposed replication of HEV (Ahmad et al., 2011). Attachment (1), binding to cellular receptor (2),  
and particle internalization (3); uncoating (4), RNA translated into nonstructural proteins (5); positive sense 
RNA replicated into negative strands (6); synthesis of subgenomic (7a) and full-length positive sense RNA 
(7b); subgenomic RNA translated into ORF2 and ORF3 proteins (8); genomic RNA packaged by capsid protein 
(9); ORF 3 associated with endomembranes (10a) or plasma membranes (10b); mature virions associated with 
ORF3 proteins and lipids released (11). Reprinted from Virus Research, Vol. 161, Imran Anmad, R. Prasida 
Holla and Shahid Jameel, Molecular Virology of hepatitis E virus, Pages No. 47-58, Copyright (2011) with 
permission from Elsevier. 
2.3.3 Viral particle structure 
 
Figure 4: Structural domains of the HEV capsid protein according to Xing el al., 2010. Shell (S) from aa 118-
317, middle (aa 318-451) and protruding (aa 452-606) domains 
The HEV capsid subunits are formed by two identical molecules (homodimers), 
which represent the main structure responsible for the virion shell (Xing et al 1999). The 
capsid protein comprises about 660 amino acids with a molecular size of approximately 
70 kda and can be divided into three different domains: S (shell), M (middle) and P 
(protruding). These domains are located in position 118-317, 318-451 and 452-606, 
7 
 
respectively (Fig. 4) (Xing et al., 2010). Another study has called the M and P domain P1 
and P2, respectively (Guu et al., 2009). 
The S domain forms the internal skeleton of the particle, forming a continuous 
capsid shell. It contains an anti-parallel jelly roll-like containing eight ß-strands with four 
short α-helices (Guu et al., 2009; Yamashita et al., 2009). The M domain has a twisted 
anti-parallel ß-barrel structure with six ß-strands and four α-helices. It is tightly 
associated to the S domain and linked to the P domain by a long proline-rich hinge 
(Yamashita et al., 2009). The association of these two domains makes it possible for the 
capsid protein dimer to change its conformation, allowing a very unique topology (Mori 
and Matsuura, 2011). The P domain is a single individual domain forming a twisted anti-
parallel ß-sheet structure. It forms dimeric spikes stabilizing protein interactions across 
the two-folds (two-fold like spikes) (Guu et al., 2009; Mori and Matsuura, 2011; 
Yamashita et al., 2009).  
2.4 HEV infection 
2.4.1 Mode of transmission 
The main route of human HEV transmission is fecal-oral. The first reported 
outbreak pointed already towards an association between ingestion of water or food 
contaminated with HEV (Aye et al., 1992; Huang et al., 1992; Skovgaard, 2007; 
Sreenivasan et al., 1984b; Wong et al., 1980). Other less common routes are vertical 
transmission (transplacental) as well as horizontal via blood transfusion or organ 
transplantation (Halac et al., 2011; Hosseini Moghaddam, 2011; Khuroo and Kamili, 
2009; Kumar et al., 2001; Panda et al., 2007; Rostamzadeh Khameneh et al., 2011; 
Tamura et al., 2007a).  
In swine different routes of transmission have been tested and it was evident that 
the main route of transmission is again fecal-oral. After becoming infected animals shed 
viral particles in feces without showing clinical symptoms (Kasorndorkbua et al., 2004). It 
has also been suggested that HEV can be transmitted from one farm to another by fecal 
contamination or the movement of people and animals (Yan et al., 2008). For instance, a 
common HEV strain has been reported among two distinct farms who shared piglets 
(Vasickova et al., 2009). 
Another study suggested that the major route of transmission in Europe is related 
to consumption of offal, wild boar or food contaminated during preparation (Wichmann et 
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al., 2008). As a foodborne pathogen HEV particles can actually be ingested via water, 
undercooked meat from swine or wild animals such as deer, crops, ingestion of mollusks 
from contaminated water or sewage (Li et al., 2007; Meng, 2011).  
2.4.2 Blood transfusion 
Positive serum samples were detected by ELISA in American and German blood 
donors (Dawson et al., 1992). Another study in Germany with samples from three 
different groups (blood donors, patient with history of acute hepatitis and patients 
positive for antibodies against other hepatitis viruses) showed that 37 % of the HEV 
seropositives had received a blood transfusion before. The authors raised the question 
of the possible transmission route (Wang et al., 1993). Afterwards many studies reported 
HEV antibodies in other European countries such as Switzerland (Lavanchy et al., 
1994), Italy (Zanetti and Dawson, 1994), Australia (Moaven et al., 1995) and Brazil 
(Parana et al., 1997). 
These findings have raised concern about the risk of transmission via blood 
transfusion. The first molecular evidence for transfusion-transmitted HEV came in 2004 
from a 67-year-old Japanese patient. The HEV sequence was highly similar to that of 
one donor sample (Matsubayashi et al., 2004). Another report is of a 21-year-old 
Japanese patient who was receiving chemotherapy to treat T-cell lymphoma and was 
diagnosed with hepatitis E after receiving multiple transfusions from at least 84 donors. 
The transfused blood aliquots were screened and HEV RNA was detected on the 
product transfused on day 26. Complete genomic sequences were identical, evidencing 
the transmission (Tamura et al., 2007a). 
2.4.3 Clinical disease (humans) 
HEV infection can cause acute liver disease which is mild and self-limited in the 
majority of cases. However, in some cases it can induce the so-called “Fulminant 
Hepatic Failure” (FHF) which is a severe acute hepatic disease with low chances of 
recovery. The non-specificity and diversity of the clinical symptoms may lead to 
misdiagnosed cases. For example it has been suggested that acute hepatitis may be 
frequently diagnosed as an unknown cause and the patient receives symptomatic 
treatment (Sherman, 2011). In addition Hepatitis E can be misdiagnosed in drug induced 
acute liver injury cases (Davern et al., 2011). 
HEV infection often manifests as subclinical disease. Usually the patients show 
typical signs and symptoms of acute liver disease, very similar to HAV infection. The 
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course can be completely asymptomatic or accompanied by fever. Clinical signs and 
symptoms including the incubation period can range from 15 to 60 days. According to 
studies in volunteers incubation periods of 36 (Balayan et al., 1983) and 30 days 
(Chauhan et al., 1993) were observed. The classical symptomatic infection can be 
divided into three phases: pre-icteric from 1-10 days, icteric from 12-15 days up to one 
month and post-icteric which is characterized by normalization of liver enzyme levels 
(Aggarwal, 2011; Panda et al., 2007).  
The pre-icteric phase is characterized by unspecific gastrointestinal symptoms 
such as nausea, vomiting and epigastric pain. The icteric phase starts suddenly as result 
of high levels of bilirubin in the tissues. It can be evidenced by jaundice, dark urine, clay 
colored feces and frequently by fever and arthralgia. Within this phase the liver functions 
are transformed and the alteration of laboratory findings such as alanine 
aminotransferases (ALT), aspartate aminotransferases (AST), gamma-
glutamyltransferases (GGT), bilirubin and prothrombin levels and serum alkaline 
phosphatase (SAP) may be noted (Srivastava et al., 2011). 
2.4.3.1 Fulminant hepatic failure  
Fulminant hepatic failure (FHF) or acute liver failure (ALF) is an acute hepatitis 
followed by encephalopathy within four weeks of the first symptoms. There is a loss of 
function of 80-90 % of the liver cells. The outcome can be classified regarding the 
appearance of encephalopathy until 24 weeks after the onset of symptoms. The 
prognosis is poor to moderate and the survival rate may range according to the course 
of the disease (O'Grady et al., 1993; Trey and Davidson, 1970; Vaquero and Blei, 2003). 
The mechanism of how HEV is related to FHF pathogenicity is not completely 
understood. The complications associated with FHF are hepatic encephalopathy, 
cerebral edema, coagulopathy, hepatic parenchyma necrosis, renal failure, pulmonary 
edema, cardiovascular disorders and coma (Acharya et al., 1996; Alam et al., 2009; 
Harry et al., 2003; Trewby et al., 1978). Once FHF is diagnosed the patient should be 
moved to an intensive care unit and the possibility of transplantation should be 
considered (Vaquero and Blei, 2003). 
2.4.3.2 HEV infection during pregnancy  
Hepatitis E in pregnant women is an explosive disease with elevated case-fatality 
rates (Khuroo and Kamili, 2003). In comparison with other hepatitis viruses, HEV is most 
frequently associated with severe complications in pregnant women (Beniwal et al., 
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2003; Jaiswal et al., 2001; Khuroo and Kamili, 2003). A study with pregnant patients 
suffering of acute viral hepatitis has shown that HEV was associated with almost half of 
the patients. In addition, vertical transmission can occur: it has been reported that all 
HEV RNA positive women have delivered HEV positive babies (Kumar et al., 2001). The 
reported outcome or complications regarding vertical transmission were miscarriage, 
abortion, mother death, neonatal death, premature delivery and self-limiting disease in 
the babies (Khuroo and Kamili, 2009). 
On the other hand, different studies have questioned the statements and 
epidemiological designs of the previous studies. Following cases during 1986 to 2006 it 
was demonstrated that the mortality and the outcome in ALF pregnant patients were not 
different than in non-pregnant women, girls, boys and men and should not be 
considered as a poor prognostic variable (Bhatia et al., 2008). Seroprevalence rates 
reported in pregnant women are similar to the general population suggesting that they 
are not more susceptible to HEV than other population groups (Cevrioglu et al., 2004; 
Oncu et al., 2006). 
2.5 HEV in animals  
In the mid-nineties there was a search for an animal reservoir of HEV. After 
experimental infection swine excreted HEV particles in the feces (Balayan et al., 1990). 
Another study found HEV IgG and also RT-PCR positive swines (Clayson et al., 1995). 
In 1997, partial genomic HEV RNA fragments infecting swine were reported for the first 
time and phylogenetic analysis confirmed that both swine and human sequences were 
closely related (Meng et al., 1997b). This discovery opened a new door in HEV 
research; swine hepatitis E viruses began to be reported from different countries.  
Domestic pigs and wild boars are now considered as the main reservoir for HEV 
genotypes 3 and 4 (Meng, 2010). However HEV RNA has been found in other animal 
species such as deer, mongoose, rabbit, rat and chicken (aHEV). In addition, anti-HEV 
antibodies have been found in various other animal species such as wild rodents, dogs, 
cats, cattle, sheep, goats and horses (see table 3) (Arankalle et al., 2001; Li et al., 
2006a; Mochizuki et al., 2006; Peralta et al., 2009; Vitral et al., 2005; Zhang et al., 
2008).  
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2.5.1 Domestic pigs 
A number of studies have reported both anti-HEV antibodies and the presence of 
HEV RNA, showing that the virus is endemic in swine herds in different countries and 
continents (Table 1).  
The prevalence of anti-HEV antibodies in swine has been shown to be age 
dependent. Antibodies against HEV in swine arise around twelve to 15 weeks of age 
and high seroprevalence rates can be observed already in two to four month-old piglets 
(Jinshan et al., 2010). However, prevalence of anti-HEV antibodies in adults are usually 
higher than in young swine in a given population (Chang et al., 2009). The IgG 
antibodies remain detectable until slaughter age (de Deus et al., 2008a; Meng et al., 
1997b) and IgM remains for five to seven weeks and is, as in humans, related to viremia 
(de Deus et al., 2008a). 
The detection rates of genomic HEV range according to age as well but seem to 
be higher in young animals, in contrast to antibody detection. Several studies from 
different countries reported that higher prevalence rates of HEV RNA have been 
detected in swine between two and four months of age (McCreary et al., 2008; 
Siripanyaphinyo et al., 2009; Ward et al., 2008; Yu et al., 2008). Although unusual, HEV 
can also be detected in older animals. For instance few studies have reported high 
prevalence rates of HEV RNA in adult and old sows in different farms in Northern Italy, 
England and Thailand (Di Bartolo et al., 2008; McCreary et al., 2008).  
Almost all subtypes from genotypes 3 and 4 have been found in swine herds 
around the world. A high viral heterogeneity can be found in the same population or 
region (Di Bartolo et al., 2008). For instance, different subtypes of genotype 4 HEV have 
been detected in swine feces from farms in the same region in Shanghai (Yan et al., 
2008).   
Table 1: Prevalence of HEV RNA (feces and/or blood) and seroprevalence found in swine in different studies. 
Genotypes are shown in parenthesis and “-” means not found/in the study. 
Country  Seroprevalence HEV RNA Reference 
Asia    
China 26.8 % - (Meng et al., 1999b) 
- 7.2 % (G4) (Zheng et al., 2006) 
- 5 % (G4) (Yan et al., 2008) 
68.3 % 5.8 %(G4) (Li et al., 2008) 
67 % 4.6 % (G3) (Zhang et al., 2008) 
- 22.3 %(G3, 
4) 
(Li et al., 2009b) 
52.2 % 8.4 % (G4) (Jinshan et al., 2010) 
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82.2 % 0.8 % (G4) (Geng et al., 2010) 
81.2 % 47.9 % (G4) (Geng et al., 2011) 
- 6.7 % (G4) (Geng et al., 2011) 
78.8 % 1.9 % (G4) (Wang et al., 2002) 
- 23.1 % (G3) (Ning et al., 2007) 
82.3 % 22.9 % (G4) (Chang et al., 2009) 
Japan  57.9 % 10.1 % (G3, 
G4) 
(Takahashi et al., 2003) 
13.2 % 14.5 % (G3) (Tanaka et al., 2004) 
55.7 % 3.9 % (G3, 
G4) 
(Takahashi et al., 2005) 
74.6 % 1.8 % (G3) (Sakano et al., 2009) 
Taiwan 37.1 % 2.63 % (g 3) (Hsieh et al., 1999) 
- 1.3 % (G3) (Wu et al., 2000) 
India 66.5 % - (Arankalle et al., 2001) 
94.7 % 12.3 % (G4) (Arankalle et al., 2003) 
- 2 % (G4) (Vivek and Kang, 2011) 
Korea - 17 % (G3) (Yu et al., 2008) 
39.5 % 1.9 %(G3) (Lee et al., 2009a) 
40.7 % - (Meng et al., 1999b) 
Thailand 30.7 % - (Meng et al., 1999b) 
64.7 % 7.75 % (G3) (Siripanyaphinyo et al., 2009) 
Mongolia 91.8 % 36.6 % (G3) (Lorenzo et al., 2007) 
Oceania    
Indonesia 73.6 % 1 % (G3) (Utsumi et al., 2011) 
New 
Caledonia 
- 6.5 % (G3) (Kaba et al., 2011) 
Bali 71.7 % 1 % (G4) (Wibawa et al., 2004) 
New 
Zeeland 
75 % 37.8 % (G3) (Garkavenko et al., 2001) 
Americas    
US - Genotype 3 (Meng et al., 1997b) 
- 35.4 % (G3) (Huang et al., 2002) 
Canada 18.2 % - (Meng et al., 1999b) 
- 34.3 % (G3) (Ward et al., 2008) 
Argentina 22.7 % 88.9 %(G3) (Munné et al., 2006) 
Brazil 24.3 % - (Vitral et al., 2005) 
- 9.6 % (G3) (dos Santos et al., 2011) 
Bolivia - 31.8 % (G3) (Dell'Amico et al., 2011) 
Africa    
Congo - 2.5 % (G3) (Kaba et al., 2010a) 
Europe    
Belgium - 7 % (G4 
and G3) 
(Hakze-van der Honing et al., 
2011) 
Czech 
Republic 
- 36.7 % (G3) (Vasickova et al., 2009) 
England - 21.5 % (G3) (McCreary et al., 2008) 
France 40.5 % 31.2 % (G3) (Kaba et al., 2009) 
16.3 % 3.4 % (G3) (Rose et al., 2011) 
Germany 49.8 %  (Baechlein et al., 2010) 
Hungary - 27.3 % (G3) (Reuter et al., 2009) 
- 21.0 % (G3) (Forgách et al., 2010) 
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Italy - 42 % (G3) (Di Bartolo et al., 2008) 
- 29.9 % (G3) (Martelli et al., 2010) 
87 % 64.6 % (G3) (Di Bartolo et al., 2011) 
The 
Netherlands 
- 15 %(G3) (Hakze-van der Honing et al., 
2011) 
Spain 25 % negative (Pina et al., 2000) 
20.4 % 18.8 % (G3) (Jiménez de Oya et al., 2011) 
71.4 %  (Peralta et al., 2009) 
- 23.3 % (G3) (Fernández-Barredo et al., 2006) 
- 37.7 % (G3) (de Deus et al., 2007) 
Sweden  - 29.6 % (G3) (Widén et al., 2011) 
2.5.2 Wild boar and deer 
The first report of HEV RNA in wild boar came from Japan and came only a few 
years after discovery of HEV in swine. During an HEV outbreak investigation in Japan in 
2003 a series of human cases was linked by epidemiological investigation to the 
consumption of uncooked wild boar liver and Sika deer meat. Nevertheless it could only 
be evidenced in deer since there were no wild boar liver left to be tested (Matsuda et al., 
2003; Tei et al., 2003). After this report wild boar samples were screened; HEV RNA has 
been detected for the first time in wild boar from Japan (Sonoda et al., 2004). 
Since then HEV has been detected in wild boar herds from different countries. For 
instance, in free-living wild boar from Japan (Nishizawa et al., 2005; Sakano et al., 2009; 
Sonoda et al., 2004) and from several European countries such as Spain, Germany, 
Hungary, Italy, the Netherlands and Sweden (Table 2) (Adlhoch et al., 2009b; de Deus 
et al., 2008b; Kaba et al., 2010b; Kaci et al., 2008; Martelli et al., 2008; Reuter et al., 
2009; Rutjes et al., 2010; Widén et al., 2011). In contrast, only a few studies have found 
HEV positive deer since the first report. HEV was reported in wild Sika deer in Japan, in 
Roe deer (Capreolus capreolus and C. rufus) in Hungary and red deer (Cervus elaphus) 
in the Netherlands (Reuter et al., 2009; Rutjes et al., 2010). 
Different from domestic swine, high detection rates of HEV RNA have been 
reported not only in young animals but also in adult wild boar (de Deus et al., 2008b; 
Martelli et al., 2008). In addition, it seems that the viral heterogeneity is higher in wild 
boar populations. Different subtypes have been reported within the same populations in 
Germany and Sweden (Adlhoch et al., 2009b; Widén et al., 2011). In Japan genotypes 
3, 4 and another lately proposed new genotype were found in wild boar (Sato et al., 
2011; Takahashi et al., 2011). So far only genotype 3 viruses have been reported in 
deer. 
14 
 
Table 2: Prevalence of HEV RNA and seroprevalence of HEV antibodies in wild boar reported in different 
studies. 
2.5.3 Other animals species 
Both anti-HEV IgG and IgM antibodies as well as HEV RNA have been found in 
mongoose specimens from Japan; mongoose HEV clusters in genotype 3 (Li et al., 
2006a; Nakamura et al., 2006). A recent study in China has reported HEV RNA in 
rabbits. Phylogenetic analysis has shown that HEV found in Chinese Rex rabbits might 
represent a novel genotype of HEV closely related to genotype 3 (Zhao et al., 2009). 
The presence of anti-HEV antibodies was reported in rats and other rodent 
species (Favorov et al., 2000; Kabrane-Lazizi et al., 1999). Later on HEV-like viruses 
have been detected in Norwegian rats (Rattus norvegicus) from Germany (Johne et al., 
2010a; Johne et al., 2010b).  
A number of serological studies have reported anti-HEV antibodies in several 
other animal species such as dogs, cows, horses, goats and wild rodents (table 3) 
(Arankalle et al., 2001; Chang et al., 2009; Geng et al., 2011; Geng et al., 2010; 
Mochizuki et al., 2006; Okamoto et al., 2004; Peralta et al., 2009; Vitral et al., 2005; 
Wang et al., 2002; Zhang et al., 2008). The meaning of presence of the antibodies in 
these species is not completely clear. For instance, in rabbits, chicken and Norwegian 
rats new viruses have been sequenced and are related to the other viral strains detected 
in humans, pigs and wild boars. This explain the presence of antibodies in these 
species, for instance the rat HEV are closely related and can react to HEV antibodies in 
humans (Dremsek et al., 2011). Regarding the other species in which only antibodies 
have been detected it is still not clear whether HEV can infect these species or some 
other viruses cross reacting with the HEV are present. 
Country Seroprevalence HEV RNA References 
Japan 8.1% 3,3% (G3 and 4) (Sato et al., 2011) 
8.6% 2.9% (G3) (Sonoda et al., 2004) 
- 2.3% (G3) (Nishizawa et al., 2005) 
4.5% 1.1% (G3) (Sakano et al., 2009) 
France  2.5% (G3) (Kaba et al., 2010b) 
Germany 24.3% 68.2% (G3) (Adlhoch et al., 2009b) 
- 5.3% (G3) (Kaci et al., 2008) 
Hungary  12.2%(G3) (Reuter et al., 2009) 
 10.7% (Forgách et al., 2010) 
Italy  25% (G3) (Martelli et al., 2008) 
Spain 28% 19.6% (G3) (de Deus et al., 2008b) 
Sweden  8.2% (G3) (Widén et al., 2011) 
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Table 3: Seroprevalence of HEV in different species. 
Family Species Country Sero-
prevalence  
References 
 
Artiodactyl Cattle India 6.1% (Arankalle et al., 2001) 
Brazil 1.5% (Vitral et al., 2005) 
 
 
 
China 
6.3% (Wang et al., 2002) 
6% (Zhang et al., 2008) 
29.3% (Chang et al., 2009) 
10.4% (Geng et al., 2010) 
25.3% (Geng et al., 2011) 
14.9% (Geng et al., 2011) 
Sheep 
 
China 9.3% (Geng et al., 2011) 
9.8% (Chang et al., 2009) 
Sheep Spain 1.9% (Peralta et al., 2009) 
Goat 
 
China 24% (Zhang et al., 2008) 
28.2% (Geng et al., 2010) 
Goat Spain 0.6% (Peralta et al., 2009) 
Horse 
 
China 16.3% (Zhang et al., 2008) 
14.3% (Geng et al., 2011) 
Carnivores Mongoose Japan 8.3% (Li et al., 2006a) 
Dog 
 
India 22.7% (Arankalle et al., 2001) 
China 17.8% (Zhang et al., 2008) 
Brazil 6.97% (Vitral et al., 2005) 
 Japan 2.4% (Mochizuki et al., 2006) 
Cat 
 
Japan 4% (Mochizuki et al., 2006) 
Japan 32.6% (Okamoto et al., 2004) 
Spain 11.1% (Peralta et al., 2009) 
Rodents Rodent India 11.2% (Arankalle et al., 2001) 
Wild rodents Brazil 50% (Vitral et al., 2005) 
Avian Chicken Brazil 20% (Vitral et al., 2005) 
 China 
 
1.9% (Zhang et al., 2008) 
2.5% (Geng et al., 2011) 
Duck China 12.8% (Zhang et al., 2008) 
3% (Geng et al., 2011) 
Pigeon  China 4.4% (Zhang et al., 2008) 
2.6 Pathogenesis and immune response 
In experimental infection with animals, viral RNA has been detected in the liver 
and a number of other tissues (bile, kidney, gallbladder, spleen, large and small 
intestines, lymph nodes and tonsils) (Bouwknegt et al., 2009; dos Santos et al., 2009; 
Leblanc et al., 2010; Lee et al., 2009b). It has been shown that HEV replicates in the 
hepatocytes (Tam et al., 1996), however there is evidence of extrahepatic replication 
sites e.g. in lymph nodes and intestinal tract tissues (Williams et al., 2001). Even if it is 
not completely clear where HEV replicates, it is feasible to postulate that the liver plays 
an important role in the disease.  
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Clinical symptoms or disease have not been associated with the presence of HEV 
in animals. Nevertheless the infection can induce a mild to moderate subclinical hepatitis 
(Martín et al., 2007). Some studies have attempted to associate the presence of HEV 
with clinical disease in animals. For example, HEV was related to hepatitis and liver 
lesions in naturally infected pigs (de Deus et al., 2008a). In addition HEVs have been 
detected in non-healthy swine: some of the positive animals showed mild to moderate 
liver lesions but have been diagnosed with other diseases such postweaning 
multysystemic wasting syndrome (de Deus et al., 2007).  
Co-infection with HEV and other viruses may induce immune system dysfunction 
in domestic swine (Savic et al., 2010). For instance, it has been shown that pigs infected 
with HEV and Porcine Circovirus 2 (PCV2) are more likely to be infected with Teno 
Torque Viruses (TTVs) (Savic et al., 2010). In addition transplacental HEV infection has 
been evidenced in aborted fetuses and suggested that the co-infection with PCV2 may 
be responsible for reproductive disturbance (Hosmillo et al., 2010).  
In humans HEV will induce mild or self-limiting disease in most cases. However in 
some cases infection might induce FHF or evolve to chronic hepatitis. The mechanism 
of liver/hepatocyte damage is still poorly understood. Accordingly it is not yet clear 
whether cell damage is caused directly by the presence of the virus in host cells or by 
host immune responses as reported for other hepatitis viruses (Rehermann and 
Nascimbeni, 2005).  
Uncomplicated or mild disease has been associated with an increase of IFN-ɣ 
and TNF-α-secreting T cells (Srivastava et al., 2011). Regarding to the innate immune 
response it has been suggested that NK and NKT cells are activated during acute 
hepatitis E (Srivastava et al., 2008). CD4+ and CD8+ seem not to be activated in the 
peripheral blood (Srivastava et al., 2007; Tripathy et al., 2012), however the presence of 
CD8+ was reported in the liver of a FHF HEV infected patient and may be involved in 
hepatitis E pathogenesis (Prabhu et al., 2011). T-cell response also seems to be 
involved in the pathogenesis of chronic hepatitis E (Suneetha et al., 2012). 
2.7 Diagnosis  
Due to its clinical and epidemiological characteristics the diagnosis of HEV may 
be challenging. It is difficult to distinguish hepatitis E from other causes of acute viral 
hepatitis and HEV may not be detected even if the correct tools are employed. The first 
assay for detection of HEV was based on immune electron microscopy (Balayan et al., 
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1983). Afterwards different serological and molecular assays (RT-PCR and qRT-PCR) 
were developed (Jothikumar et al., 2006; Li et al., 2006b). 
In general the diagnosis includes the detection of IgG and IgM antibodies against 
HEV as well as HEV RNA in serum and feces (Teshale and Hu, 2011). Recently some 
cell lines were shown to be permissive for HEV infection (Okamoto, 2011b; Tanaka et 
al., 2007), however this has not been validated so far as a diagnostic test for HEV. 
A proper diagnose of hepatitis E in humans should combine markers for liver 
function, the appropriate serological test and molecular detection. The results from 
serological tests should consider the epidemiological situation. For instance a positive 
antibody titre in an endemic region may be meaningless. The detection of HEV in 
animals indicates contact with HEV and can be useful for epidemiological surveys and 
risk analysis studies.  
2.7.1 Serological assays  
The production of the first cDNA HEV clone allowed the expression of 
recombinant proteins (Tam et al., 1991). This led to a number of commercial and in-
house assays based on different recombinant proteins and synthetic peptides from 
animal and human origin (Goldsmith et al., 1992; Meng et al., 1997a; Meng et al., 
1998a). All three HEV ORFs have shown different antigenic regions (He et al., 1995; 
Khudyakov et al., 1994; Purdy et al., 1992). However, ORF 2 is more immunogenic and 
definitely contains a great number of antigenic domains which were target for most 
serological assays (Table 4). Currently there are a number of commercial and in-house 
tests including ELISA and Western blot-based techniques (table 5). 
Table 4: Different genomic regions and expression systems for expression of the HEV capsid protein. 
Systems used to express HEV proteins 
Expression System Protein/Region References 
Baculovirus  (pupae of 
silkworm, SF9,  
Trichoplusia ni 
larvae) 
ORF 2: 55 kda based on Sar55 
isolate 
(Arankalle et al., 2003; Arankalle 
et al., 2001; de Deus et al., 
2008b; Hsieh et al., 1999; Meng 
et al., 1999a; Pina et al., 2000) 
ORF 2: 111 - 660aa (G4 HE-J1 
strain) 
(Lorenzo et al., 2007; Mizuo et 
al., 2002; Sonoda et al., 2004; 
Takahashi et al., 2003; Wibawa 
et al., 2004) 
ORF 2: 111 - 660aa (G3) (Jiménez de Oya et al., 2011; 
Jiménez de Oya et al., 2009) 
E .Coli (GST) ORF 2: 394 - 604 (G1) (Wang et al., 2002) 
ORF 2: 394 - 604 (Chang et al., 2009) 
ORF 2: 452 - 617 (Obriadina et al., 2002; Vitral et 
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al., 2005) 
Table 5: Commercial kits for detection of anti-HEV antibodies.  
Company References 
Abott (Munné et al., 2006; Pina et al., 
2000) 
Genelabs Diagnostic (Adlhoch et al., 2009b; Lee et al., 
2009a; Wu et al., 2000)  
Genelabs Inc., Singapore (Wang et al., 2002) 
MP Biomedicals Asia Pacific previously Genelab® 
Diagnostics, Singapore 
(Leblanc et al., 2007) 
Viragent HEV-Ab kit, Cosmic Corporation (Siripanyaphinyo et al., 2009) 
Institute of Immunology, Tokyo, Japan (Utsumi et al., 2011) 
Wan Tai Pharmaceutica (Chang et al., 2009; Zhang et al., 
2008; Zheng et al., 2006) 
recomWell HEV and recomLine HEV IgG, Mikrogen (Adlhoch et al., 2009b) 
Adaltis EIAgen kits, Adaltis Italia (Kaba et al., 2009) 
ELISA (IgG and IgM) kit BioChain  (Di Bartolo et al., 2011) 
2.7.2 RT-PCR and qRT-PCR 
RT-PCR has been employed for diagnosis of HEV. Other techniques for detection 
of genomic HEV have been successfully used such as Southern Blot hybridization 
combined with reverse transcription (van der Poel et al., 2001). The first amplification of 
a HEV genome has taken place together with the first isolation of HEV cDNA from bile of 
an experimentally infected macaque using a random primer strategy (Reyes et al., 
1990). Afterwards different RT-PCR setups with a number of primers were used in order 
to detect different regions of the HEV genome.  
In swine and other animals the detection of HEV in both serum and feces is rather 
difficult in comparison with humans as animals do not present clinical symptoms. 
Prevalence rates can range according to the material used for diagnosis and factors 
related to the primers such as specificity, location and size of target genomic region. 
Prevalence can increase when more than one kind of sample (e.g. liver, bile, serum, 
feces) is used (Di Bartolo et al., 2011); for instance it has been reported that the 
detection rate of HEV RNA is higher in bile than in other organs, feces and serum (de 
Deus et al., 2007). Amplification using different genomic regions based primers show 
differences in sensitivity and may produce false negative results when different 
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genotypes are involved (Arankalle et al., 2003; Fogeda et al., 2009). It has been 
suggested that smaller PCR products may be amplified easier due to RNA degradation 
(Kaci et al., 2008).  
2.8 Epidemiology 
2.8.1 The virtual epidemiological transition 
Since its discovery hepatitis E virus has been associated with infectious hepatitis 
outbreaks in Asia, Africa, the Middle East and Central America. The occurrence of 
hepatitis E has been linked to poor sanitary conditions and was considered a disease of 
developing countries for the last twenty years (Aggarwal and Naik, 2009; Viswanathan, 
1957). At the end of the eighties until the early nineties it was unthinkable that hepatitis 
E would be diagnosed in developed countries (Scharschmidt, 1995). Nevertheless 
antibodies against HEV in healthy individuals and blood donors from Europe and North 
America could not be explained. In addition to traveler associated sporadic cases in 
Europe and in North America (Skaug et al., 1994) several autochthonous cases were 
reported in patients without travel history in the US, Europe, Australia and New Zealand 
(Mast et al., 1996; Preiss et al., 2006). 
The first detection of HEV in domestic swine has added an important feature to 
disease epidemiology. The genetic proximity with human viruses raised the possibility of 
an animal reservoir. The viruses were revealed to be present in domestic swine and wild 
boar populations in both developing and developed countries (Meng, 2010; Meng et al., 
1997b). 
It became clear that autochthonous cases were more frequent than previously 
recognized in developed countries (Clemente-Casares et al., 2003). Nowadays HEV is 
considered endemic in countries such as Belgium, England, France, Germany, Italy, the 
Netherlands, Spain, the US (Borgen et al., 2008; Dalton et al., 2008; Hakze-van der 
Honing et al., 2011; Meng, 2011; Romanò et al., 2011; van der Poel et al., 2001; 
Wichmann et al., 2008). 
2.8.2 Geographical distribution 
The four HEV genotypes are distributed worldwide and prevalence ranges 
between the different continents and between different socioeconomic situations (Dalton 
et al., 2008). The Genotype 1 was initially found in Asian countries such as Bangladesh 
and Myanmar (Sugitani et al., 2009; Tam et al., 1991; Yin et al., 1994) and in African 
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countries such as Chad and Morocco (van Cuyck et al., 2003). Genotype 2 sequences 
have been detected in Mexico and Nigeria (Huang et al., 1992; Lu et al., 2006), 
genotype 3 in the US, Japan, Argentina, Brazil and in European countries such as 
Belgium, France, Germany, Hungary, Italy, the Nederlands, the United Kingdom (Banks 
et al., 2004; dos Santos et al., 2009; Fukuda et al., 2007; Reuter et al., 2009), Genotype 
4 sequences in China, Taiwan and Japan (Inoue et al., 2009; Liu et al., 2012).  
Genotypes 1 and 4 have been reported in a recent study from Germany. A GT 1 
patient had been traveling to outside Europe but a GT 4 patient was confirmed as an 
autochthonous case (Wichmann et al., 2008). Recently, genotype 4 has been also 
detected in swine from Belgium being the first report of GT 4 in pigs in Europe; however 
it remains unclear how the GT 4 strain was introduced into the European swine 
population (Hakze-van der Honing et al., 2011).  
Multiple genotypes might occur in the same country, population or even in the 
same individual (human or animal) (Li et al., 2009b). The distribution of the various HEV 
genotypes in both human and animal populations in China (where genotypes 1, 3 and 4 
are present) is a very good example of how complex the geographical distribution can 
be (figure 5). Accordingly it has been suggested that the incidence of infection has 
decreased with genotype 3 and increased with genotype 4 in the swine population in 
Shanghai.  
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Figure 5: Map of China showing the different HEV strains (Genotypes and subtypes) found in both human and 
animal population (from Zhu et al., 2011 with permission
2
). Reprinted from Journal of Clinical Virology, Vol. 
52, Yu-Min Zhu,Shi-Juan Dong,Fu-Sheng Si,Rui-Song Yu,Zhen Li,Xiao-Ming Yu,Si-Xiang Zou, Swine and 
human hepatitis E virus (HEV) infection in China, Pages No. 155-157, Copyright (2011)  with permission from 
Elsevier. 
2.8.3 Zoonotic aspects of HEV infection  
The first evidence for zoonotic transmission of HEV was reported in association 
with the ingestion of deer meat. Genomic sequences of the viruses found in frozen deer 
meat matched 100 % to the ones recovered from HEV patients (Tei et al., 2003). Similar 
results have been reported in other cases which involved wild boar and pork meet from 
Japan (Li et al., 2005b; Masuda et al., 2005; Miyashita et al., 2012). In addition HEV 
RNA has been detected in commercial pig livers bought in local groceries in the US, 
Japan, France and the Netherlands (Bouwknegt et al., 2007; Colson et al., 2010; Yazaki 
et al., 2003).  
HEV sequences from genotypes 3 and 4 found in swine and wild boar are closely 
related to those reported from humans (Siripanyaphinyo et al., 2009); (Zheng et al., 
2006). In a study including 42 patients with hepatitis E it was shown that the viral strains 
were closely related to European swine strains (Legrand-Abravanel et al., 2009). 
Genotypes 1 and 2 could not be found in swine in regions where they were 
prevalent in the human population. For instance, in India, where genotype 1 HEV is 
endemic in humans, it was shown that only genotype 4 is endemic in the swine 
population (Arankalle et al., 2003). Similar results were found in study in Thailand and 
Mexico where HEV genotypes 1 and 2 were detected in the human population but only 
HEV genotype 3 has been found in pigs (Cooper et al., 2005). Experimental studies led 
to similar results. Domestic pigs were inoculated with both swine GT 3 and human GT 1 
viruses, but only the swine viruses could be recovered (Meng et al., 1998b). In another 
experimental study intergenotype chimeric viruses were inoculated into swine. The two 
chimeras with recombinant viruses from GT 1 replaced with GT 3 and GT 4 capsid 
protein were not infective to swine; in contrast, a recombinant GT 3 infectious clone with 
GT 4 capsid was able to infect domestic pigs (Feagins et al., 2011).  
2.9 Prevention and control 
2.9.1 Prevention and prophylaxis  
In the developing countries good sanitation conditions such as access to clean 
water and sewerage systems are fundamental in the control of hepatitis E outbreaks. 
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For instance, the use of chlorination reduces the amount of fecal coliforms and 
contributes to the control of hepatitis E (Naik et al., 1992). In developed countries the 
consumption of raw or undercooked meat and meat products from swine, wild boar and 
deer should be avoided. 
Few measures can be applied in order to prevent vertical transmission of HEV. 
The presence of HEV RNA and Anti-HEV IgG has been reported in colostrum, but HEV 
infected mothers can safely breastfeed. Close contact (mother-baby) should be avoided 
only if acute disease (with viremia) is present (Chibber et al., 2004; Kumar et al., 2001). 
2.9.2 Vaccines  
At least two distinct recombinant HEV vaccines went to clinical trials (Li et al., 
2005a; Shrestha et al., 2007; Zhu et al., 2010).  
One vaccine is based on a recombinant capsid protein expressed via the 
baculovirus system using Spodoptera frugiperda (Fall armyworm) cells and produced by 
GlaxoSmithKline®. The vaccine seems to be efficient in preventing hepatitis E (Shrestha 
et al., 2007), but it has been stated that there were no plans for further development or 
commercial use of the vaccine (Holmberg, 2010). In addition the design of the clinical 
trial has been a subject of criticism due to the bias such as predominance of young 
males, absence of children, pregnant women and patients with chronic liver disease 
(Goel and Aggarwal, 2011). 
The apparently most promising vaccine is called “HEV 239” and is based on a 
recombinant peptide corresponding to aa 368 to 606 of the capsid protein of a genotype 
1 isolate. It is expressed in bacterial cells (E. coli) and produced by Wantai Biological 
Pharmaceutical®, China (Li et al., 2005a). The vaccine has passed the clinical trials 
phase 2 and has been deemed safe and immunogenic in humans (Zhang et al., 2009). 
Recently the vaccine has undergone the phase 3 clinical trial and only a few mild 
adverse reactions were observed. According, “HEV 239” was well tolerated and efficient 
to prevent hepatitis E in the general adult population (Zhu et al., 2010). Later the vaccine 
was reported to be safe even for pregnant women and the fetus (Wu et al., 2011). It is 
expected that this vaccine will be available on the market soon. 
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3 Materials and Methods 
3.1 Materials 
3.1.1 Cells 
 Origin 
A549 (adenocarcinom human alveolar basal 
epithelial cells) 
Institute of Virology, FB 10, 
JLU Gießen  
E. coli TOP 10 (chemically competent cells) Invitrogen 
E. coli K12 JM109 competent E. coli cells, 
Institute of Virology, Gießen  
Rosetta cells Institute of Virology, Gießen  
QIAGEN EZ Competent Cells Qiagen 
 
3.1.2 Virus and antibodies 
 Origin 
Hepatis E Virus (infected liver fragment) Central Veterinary Institute of 
Wageningen University and Research 
Centre, The Netherlands, kindly provided 
by from Prof Dr. Wim van der Poel 
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(Bouwknegt et al 2008) 
Peroxidase Goat anti-Swine IgG Dianova  
HEV infected human serum Virus diagnostic, UKGM, Gießen  
Peroxidase Goat anti-Human IgG Dianova  
Anti-His Antibody Institute of Virology, Gießen 
Anti-Ubiquitin mAb Institute of Virology, Gießen 
3.1.3 Samples 
3.1.3.1 Sera and fecal samples 
A total of 105 fecal and 600 serum samples were collected between 2003 and 
2006 in a previous survey in pigs throughout Germany (table 7). Additionally, 124 wild 
boar sera collected in 2008 for the Classical Swine Fever Virus survey from Hesse State 
were kindly provided by “Landesbetrieb Hessisches Landeslabor, Gießen” (table 6). 
Further 145 sera samples from semi-intensive wild boars from Morroco were collected. 
Information about the sample collection is shown in table 8. 
3.1.3.2 Samples origin  
Table 6: List of wild boar sera samples from Hesse State. 
HEV Wild Boars 
Sample Identification 
Number Reference Origin 
WB 1 U-445/1 Rheingau-Taunus-Kreis 
WB 2 U-445/2 Rheingau-Taunus-Kreis 
WB 3 U-445/3 Rheingau-Taunus-Kreis 
WB 4 U-447/1 Rheingau-Taunus-Kreis 
WB 5 U-447/2 Rheingau-Taunus-Kreis 
WB 6 U-447/4 Rheingau-Taunus-Kreis 
WB 7 U-447/7 Rheingau-Taunus-Kreis 
WB 8 U-447/9 Rheingau-Taunus-Kreis 
WB 9 U-447/10 Rheingau-Taunus-Kreis 
WB 10 U-448/1 Rheingau-Taunus-Kreis 
WB 11 U-448/2 Rheingau-Taunus-Kreis 
WB 12 U-448/5 Rheingau-Taunus-Kreis 
WB 13 U-471/1 Groß-Gerau 
WB 14 U-471/2 Groß-Gerau 
WB 15 U-471/3 Groß-Gerau 
WB 16 U-472/2 Heppenheim 
WB 17 U-472/4 Heppenheim 
WB 18 U-472/5 Heppenheim 
WB 19 U-515/1 Lahn-Dill-Kreis/Wetzlar 
WB 20 U-515/2 Lahn-Dill-Kreis/Wetzlar 
WB 21 U-601/3 Limburg 
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WB 22 U-682/3 Wiesbaden 
WB 23 U-682/6 Wiesbaden 
WB 24 U-686/3 Wiesbaden 
WB 25 U-690/8 Lahn-Dill-Kreis/Wetzlar 
WB 26 U-544/2 Frankfurt 
WB 27 U-544/1 Frankfurt 
WB 28 U-517/1 Frankfurt 
WB 29 U-515/4 Lahn-Dill-Kreis/Wetzlar 
WB 30 U-515/3 Lahn-Dill-Kreis/Wetzlar 
WB 31 U-544/3 Frankfurt 
WB 32 U-544/4 Frankfurt 
WB 33 U-544/5 Frankfurt 
WB 34 U-571/4 Marburg-Biedenkopf/Lahn 
WB 35 U-571/5 Marburg-Biedenkopf/Lahn 
WB 36 U-571/6 Marburg-Biedenkopf/Lahn 
WB 37 U-601/1 Limburg 
WB 38 U-601/2 Limburg 
WB 39 U-654/5 Frankenberg 
WB 40 U-738 Marburg 
WB 41 U-739/2 Marburg 
WB 42 U-690/9 Lahn-Dill-Kreis/Wetzlar 
WB 43 U-690/13 Lahn-Dill-Kreis/Wetzlar 
WB 44 U-691/2 Lahn-Dill-Kreis/Wetzlar 
WB 45 U-692/6 Lahn-Dill-Kreis/Wetzlar 
WB 46 U-692/11 Lahn-Dill-Kreis/Wetzlar 
WB 47 U-654/1 Frankenberg 
WB 48 U-654/2 Frankenberg 
WB 49 U-654/3 Frankenberg 
WB 50 U-654/4 Frankenberg 
WB 51 U-474/2  
WB 52 U-747/10 Waldeck-Frankenberg 
WB 53 U-766/3 Hochtaunuskreis 
WB 54 U-766/7 Hochtaunuskreis 
WB 55 U-766/12 Hochtaunuskreis 
WB 56 U-766/15 Hochtaunuskreis 
WB 57 U-804/2 Offenbach am Main 
WB 58 U-804/4 Offenbach am Main 
WB 59 U-747/11 Frankenberg 
WB 60 U-766/1 Hochtaunuskreis 
WB 61 U-739/6 Marburg 
WB 62 U-740/2 Lahn-Dill-Kreis/Wetzlar 
WB 63 U-740/3 Lahn-Dill-Kreis/Wetzlar 
WB 64 U-1138/29 Hochtaunuskreis 
WB 65 U-1138/33 Hochtaunuskreis 
WB 66 U-1138/26 Hochtaunuskreis 
WB 67 U-1138/15 Hochtaunuskreis 
WB 68 U-1138/13 Hochtaunuskreis 
WB 69 U-1138/10 Hochtaunuskreis 
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WB 70 U-1114/10 Frankenberg 
WB 71 U-1114/13 Frankenberg 
WB 72 U-1114/7 Frankenberg 
WB 73 U-1114/5 Frankenberg 
WB 74 U-1114/3 Frankenberg 
WB 75 U-1087/43 Lahn-Dill-Kreis/Wetzlar 
WB 76 U-1087/36 Lahn-Dill-Kreis/Wetzlar 
WB 77 U-1087/21 Lahn-Dill-Kreis/Wetzlar 
WB 78 U-1087/11 Lahn-Dill-Kreis/Wetzlar 
WB 79 U-1087/10 Lahn-Dill-Kreis/Wetzlar 
WB 80 U-950/2 Giessen 
WB 81 U-950/1 Giessen 
WB 82 U-971/14 Hochtaunuskreis 
WB 83 U-971/3 Hochtaunuskreis 
WB 84 U-971/15 Hochtaunuskreis 
WB 85 U-971/16 Hochtaunuskreis 
WB 86 U-971/19 Hochtaunuskreis 
WB 87 U-971/18 Hochtaunuskreis 
WB 88 U-971/22 Hochtaunuskreis 
WB 89 U-1087/4 Lahn-Dill-Kreis/Wetzlar 
WB 90 U-949/9 Lahn-Dill-Kreis/Wetzlar 
WB 91 U-925/6 Marburg-Biedenkopf/Lahn 
WB 92 U-925/1 Marburg-Biedenkopf/Lahn 
WB 93 U-806/2 Groß-Gerau 
WB 94 U-804/8 Offenbach am Main 
WB 95 U-804/7 Offenbach am Main 
WB 96 U-804/5 Offenbach am Main 
WB 97 U-1022/4 Marburg 
WB 98 U-1022/3 Marburg 
WB 99 U-1022/2 Marburg 
WB 100 U-1022/1 Marburg 
WB 101 U-1114/1 Limburg 
WB 102 U-1114/3 Limburg 
WB 103 U-949/19 Lahn-Dill-Kreis/Wetzlar 
WB 104 U-949/15 Lahn-Dill-Kreis/Wetzlar 
WB 105 U-949/13 Lahn-Dill-Kreis/Wetzlar 
WB 106 U-1088/3 Frankenberg 
WB 107 U-1088/1 Frankenberg 
WB 108 U-1034/22 Limburg 
WB 109 U-1034/20 Limburg 
WB 110 U-1034/16 Limburg 
WB 111 U-1034/15 Limburg 
WB 112 U-1034/12 Limburg 
WB 113 U-1034/5 Limburg 
WB 114 U-1041/9 Lahn-Dill-Kreis/Wetzlar 
WB 115 U-1056/25 Rheingau-Taunus-Kreis 
WB 116 U-1056/2 Rheingau-Taunus-Kreis 
WB 117 U-1041/1 Lahn-Dill-Kreis/Wetzlar 
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WB 118 U-1036/2 Limburg 
WB 119 U-1041/5 Lahn-Dill-Kreis/Wetzlar 
WB 120 U-1036/1 Limburg 
WB 121 U-1056/1 Rheingau-Taunus-Kreis 
WB 122 U-1022/7 Marburg-Biedenkopf/Lahn 
WB 123 U-1041/2 Lahn-Dill-Kreis/Wetzlar 
WB 124 U-1041/15 Lahn-Dill-Kreis/Wetzlar 
Table 7: List of domestic swine feces samples collected in Germany. 
HEV Swine 
Sample Identification 
Number Reference 
1 KP63SW/M 10/04 
2 KP105 - 5SW 
3 KP72 SW-M5 3/1/04 
4 KP103 SW-3 23.08.04 
5 KP42 SW-JV 7891 - 1.10.03 
6 KP92 SW-1 10.08.04 
7 KP100 SW-5 16.08.04 
8 KP108 SW-8 23.8.04 
9 KP126SW 
10 KP 34SW-JV243 1.3.08 
11 KP 36SW JC376 
12 KP37 SWJV377/01.10.03 
13 KP54SW My5/11.02.04 
14 KP98SW 3/16.8.04 
15 KP106SW 23.8.04 
16 KP112SW Schwarzweisschen 
17 KP113SW Rosarot 
18 KP122SW 
19 KP23SW My 14/16.8.03 
20 KP33SW JV186 1.10.03 
21 KP43SW JV7892/1.10.03 
22 KP52SW My3/11.2.04 
23 KP55SW My6/11.2.04 
24 KP60SW M552/03 
25 KP97SW 2/16.8.04 
26 KP117SW 
27 KP58SW M626/03 
28 KP124SW 
29 KP75SW M53/2/04 
30 KP24SW My 15/16.08.03 
31 #18483/03 KP9SW 
32 KP48SW 230/03 5 
33 KP65SW M15/04 
34 KP127SW 
35 KP95 Sw 4/10.08.04 
36 KP87SW Kw 2/2.6.04 
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37 KP120 SW 
38 KP50SW My 1/11.2.04 
39 KP12SW My 3/6.8.03 Kot sw 
40 KP38SW JV378/1.10.03 
41 KP32SW JV181/1.10.03 
42 KP73SW M54/1/04 
43 KP57SW M633/03 
44 KP39SW JV379/1.10.03 
45 KP101SW 1 Schwein 23.08.04 
46 KP78SW K100/04 
47 KP69 SW M24/04 
48 KP67 SW 21/04 
49 KP11SW My 2/6.8.03 Kot sw 
50 KP21SW My12/4.8.03 
51 KP102SW 
52 KP81SW 
53 KP56SW 
54 KP35SW JV175/1.10.03 
55 KP41SW JV7802/1.10.03 
56 KP93 
57 KP123 
58 KP90 
59 KP31 
60 KP119 
61 KP94SW 
62 KP19SW 
63 KP28SW 
64 KP51SW 
65 KP107 
66 KP18 
67 KP89 
68 KP46 
69 KP91 
70 KP16 
71 KP79 
72 KP121 
73 KP25 
74 KP76SW 
75 KP86SW 
76 KP26SW 
77 KP10SW 
78 KP59SW 
79 KP80SW 
80 KP45SW 
81 KP68SW 
82 KP30SW 
83 KP77SW 
84 KP15SW 
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85 KP29SW 
86 KP88SW 
87 KP61SW 
88 KP74SW 
89 KP14SW 
90 KP99SW 
91 KP13SW 
92 KP40SW 
93 KP125SW 
94 KP17 
95 KP22 
96 KP96 
97 KP27 
98 KPSw98 
99 KPSw99 
100 KPSw100 
101 KPSw101 
102 KPSw102 
103 KPSw103 
104 KPSw104 
105 KPSw105 
Table 8: List of serum samples of semi-intensive wild boar from Morocco. 
HEV Wild boar (Morocco)  
Reference Sex Date of birth Date of collection 
A (9F01) Female Jan 2009 21.03.2010 
B (9F02) Female Jan 2009 21.03.2010 
C (9F03) Female Jan 2009 21.03.2010 
D (9F04) Female Jan 2009 21.03.2010 
E (9F05) Female Jan 2009 21.03.2010 
F (9F06) Female Jan 2009 21.03.2010 
G (9F07) Female Jan 2009 21.03.2010 
H (9F08) Female Jan 2009 21.03.2010 
I (9F09) Female Jan 2009 21.03.2010 
J (9F10) Female Jan 2009 21.03.2010 
K (9F11) Female Jan 2009 21.03.2010 
L (9F12) Female Jan 2009 21.03.2010 
M (9F13) Female Jan 2009 21.03.2010 
N (9F14) Female Jan 2009 21.03.2010 
O (9F15) Female Jan 2009 21.03.2010 
P (9F16) Female Jan 2009 21.03.2010 
Q (9F17) Female Jan 2009 21.03.2010 
R (9F18) Female Jan 2009 21.03.2010 
S (9F19) Female Jan 2009 21.03.2010 
T (9F20) Female Jan 2009 21.03.2010 
U (9F21) Female Jan 2009 21.03.2010 
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V (9F22) Female Jan 2009 21.03.2010 
W (9F23) Female Jan 2009 21.03.2010 
X (9F24) Female Jan 2009 21.03.2010 
Y (9F25) Female Jan 2009 21.03.2010 
Z (9F26) Female Jan 2009 21.03.2010 
AA (9F27) Female Jan 2009 21.03.2010 
AB (9F28) Female Jan 2009 21.03.2010 
AC (9F29) Female Jan 2009 21.03.2010 
AD (9F30) Female Jan 2009 21.03.2010 
AE (9F31) Female Jan 2009 21.03.2010 
AF (9F32) Female Jan 2009 21.03.2010 
AG (9F33) Female Jan 2009 21.03.2010 
AH (9F34) Female Jan 2009 21.03.2010 
AI (8F01) Female Apr 2008 21.03.2010 
AJ (8F02) Female Apr 2008 21.03.2010 
AK (8F03) Female Apr 2008 21.03.2010 
AL (8F04) Female Apr 2008 21.03.2010 
AM (8F05) Female Apr 2008 21.03.2010 
AN (8F06) Female Apr 2008 21.03.2010 
AO (8F07) Female Apr 2008 21.03.2010 
AP (8F08) Female Apr 2008 21.03.2010 
AQ (8F09) Female Apr 2008 21.03.2010 
AR (8F10) Female Apr 2008 21.03.2010 
AS (8F11) Female Apr 2008 21.03.2010 
AT (8F12) Female Apr 2008 21.03.2010 
AU (8F13) Female Apr 2008 21.03.2010 
AV (8F14) Female Apr 2008 21.03.2010 
AW (8F15) Female Apr 2008 21.03.2010 
AX (8F16) Female Apr 2008 21.03.2010 
AY (8F17) Female Apr 2008 21.03.2010 
AZ (8F18) Female Apr 2008 21.03.2010 
BA (8F19) Female Apr 2008 21.03.2010 
BB (8F20) Female Apr 2008 21.03.2010 
BC (8F21) Female Apr 2008 21.03.2010 
BD (8F22) Female Apr 2008 21.03.2010 
BE (8F23) Female Apr 2008 21.03.2010 
BF (8F24) Female Apr 2008 21.03.2010 
BG (8F25) Female Apr 2008 21.03.2010 
BH (9F01) Female Jan 2009 21.03.2010 
BI (9F02) Female Jan 2009 21.03.2010 
BJ (9F03) Female Jan 2009 21.03.2010 
BK (9F04) Female Jan 2009 21.03.2010 
BL (9F05) Female Jan 2009 21.03.2010 
BM (9F06) Female Jan 2009 21.03.2010 
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BN (9F07) Female Jan 2009 21.03.2010 
BO (9F08) Female Jan 2009 21.03.2010 
BP (9F09) Female Jan 2009 21.03.2010 
BQ (9F10) Female Jan 2009 21.03.2010 
BR (9F11) Female Jan 2009 21.03.2010 
BS (9F12) Female Jan 2009 21.03.2010 
BT (9F13) Female Jan 2009 21.03.2010 
BU (9F14) Female Jan 2009 21.03.2010 
BV (9F15) Female Jan 2009 21.03.2010 
BW (9F16) Female Jan 2009 21.03.2010 
BX (9F17) Female Jan 2009 21.03.2010 
BY (9F18) Female Jan 2009 21.03.2010 
BZ (9F19) Female Jan 2009 21.03.2010 
CA (9F20) Female Jan 2009 21.03.2010 
CB (9F21) Female Jan 2009 21.03.2010 
CC (9F22) Female Jan 2009 21.03.2010 
CD (9F23) Female Jan 2009 21.03.2010 
CE (9F24) Female Jan 2009 21.03.2010 
CF (9F25) Female Jan 2009 21.03.2010 
CG (9F26) Female Jan 2009 21.03.2010 
CH (9F27) Female Jan 2009 21.03.2010 
CI (9F28) Female Jan 2009 21.03.2010 
CJ (9F29) Female Jan 2009 21.03.2010 
CK (9F30) Female Jan 2009 21.03.2010 
CL (9F31) Female Jan 2009 21.03.2010 
CM (8F01) Female Oct 2008 22.03.2010 
CN (7F01) Female 2007 22.03.2010 
CO (8F02) Female Oct 2008 22.03.2010 
CQ (7F01) Female Apr 2007 22.03.2010 
CR (7F02) Female Apr 2007 22.03.2010 
CS (7F03) Female Apr 2007 22.03.2010 
CU (8F12) Female Apr 2008 22.03.2010 
CV (7F05) Female Apr 2008 22.03.2010 
CW (8F01) Female Apr 2008 22.03.2010 
CX (9F01) Female Jan 2009 22.03.2010 
CY (8F02) Female Apr 2008 22.03.2010 
CZ (8F03) Female Apr 2008 22.03.2010 
DA (8F04) Female Apr 2008 22.03.2010 
DB (8F05) Female Apr 2008 22.03.2010 
DC (9F02) Female Jan 2009 22.03.2010 
DD (8F06) Female Apr 2008 22.03.2010 
DE (8F07) Female Apr 2008 22.03.2010 
DG (9F03) Female Jan 2009 22.03.2010 
DH (8F09) Female Apr 2008 22.03.2010 
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DI (8F10) Female Apr 2008 22.03.2010 
DJ (8F11) Female Apr 2008 22.03.2010 
DK (9F04) Female Jan 2009 22.03.2010 
DL a (9F05) Female Jan 2009 22.03.2010 
DM (7F02) Female Apr 2007 22.03.2010 
DN (7F04) Female Apr 2007 22.03.2010 
DO (7F01) Female 2007 22.03.2010 
DP (7F02) Female 2007 22.03.2010 
DR (7F03) Female 2007 22.03.2010 
DS (9F02) Female Jan 2009 22.03.2010 
DT (9F01) Female Aug 2009 22.03.2010 
DU (9F02) Female Aug 2009 22.03.2010 
DV (9F03) Female Aug 2009 22.03.2010 
DW (9F04) Female Aug 2009 22.03.2010 
DX (9F05) Female Oct 2009 22.03.2010 
DY (9F06) Female Oct 2009 22.03.2010 
DZ (9F07) Female Oct 2009 22.03.2010 
EB (5317) Male Jan 2009 22.03.2010 
EC (3089) Male Jan 2009 22.03.2010 
EE (9283) Male Jan 2009 22.03.2010 
EF (6252) Male Jan 2009 22.03.2010 
EG (4366) Male Jan 2009 22.03.2010 
EH (5463) Male Jan 2009 22.03.2010 
EI (5661) Male Dec 2008 22.03.2010 
EJ (1981) Male Jan 2009 22.03.2010 
EL (3067) Male Mar 2009 22.03.2010 
EM (0270) Male Jan 2009 22.03.2010 
EN (5389) Male Jan 2009 22.03.2010 
EO (5914) Male Jan 2009 22.03.2010 
EP (1940) Male Apr 2008 22.03.2010 
ET (5519) Male Apr 2008 22.03.2010 
EV (5676) Male Apr 2008 22.03.2010 
EZ (6313) Male Apr 2008 22.03.2010 
FD (9748) Male Apr 2007 22.03.2010 
3.1.3.3 Liver samples (hepatocytes) 
Liver samples were collected in the slaughterhouse in Giessen. 
3.1.4 Enzymes and enzyme buffers 
Buffer 1 New England Biolabs 
Buffer 2 New England Biolabs 
Buffer 3 New England Biolabs 
Buffer 4 New England Biolabs 
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Buffer ECO RI New England Biolabs 
ECO RI New England Biolabs 
ECO RV New England Biolabs 
Spe I New England Biolabs 
AlwN1 New England Biolabs 
BamHI New England Biolabs 
SacII New England Biolabs 
AleI   New England Biolabs 
T4-DNA-Ligase New England Biolabs 
T4-Ligase Puffer New England Biolabs 
Superscript II RNAse H reverse Transkriptase 200 U/µl Invitrogen  
3.1.5 Prefabricated media and kits 
QIAamp Viral RNA Mini Kit Qiagen 
Rneasy Mini Kit Qiagen 
One Step RT-PCR Kit Qiagen 
QIAquick Gel Extraction Kit Qiagen 
QIAprep Spin Miniprep Kit Qiagen 
QIAex II Extraction Kit Qiagen 
TOPO TA Cloning Kit Invitrogen  
NucleoBond® Xtra Midi Kit (Midipred)  Macherey-Nagel 
3.1.6 Reagents and chemicals 
1 Kb DNA ladder  Invitrogen  
100 bp DNA ladder Invitrogen  
Acrylamide  Fluka 
Agar-Agar Difco 
Agarose NEEO ultra-quality Roth 
AgarPlaquePlus®Agarose  BD Biosciences 
Pharmingen 
Amonium persulfate AmpliChen  
Ampicillin Serva 
Bacto Tryptone  Difco 
Bovine Serum Albumin (BSA) Gibco-BRL 
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Red Bromophenol Sigma 
Dimethyl sulfide (DMSO) Sigma 
Deoxynucleotide triphosphastes (dNTPs) Roth 
Ethidium bromide Roth 
Ethanol Roth 
Ethylenediaminetetraacetic acid (EDTA) Roth 
Glycine  Roth 
Isopropanol Roth 
Methylamine wolfram Plano 
β-mercaptoethanol Merk 
Octyl glucoside Fluka 
Penicillin/Streptomycin Sigma 
Phenol red Riedel-de Haen AG 
Sodium dodecyl sulfate (SDS) ICN 
Tetramethylethylenediamine (TEMED) Boehringer Mannheim 
Tris(hydroxymethyl)aminomethane (TRIS) Boehringer Mannheim 
Triton X-100  Fluka 
Trypan blue Serva 
Polysorbate 20 (Tween 20) Fluka 
Ultra Pure Sequa Gel Complete Buffer National Diagnostics 
Urea United States 
Biochemical 
3.1.7 All-purpose medium and buffers 
Ca/Mg Solution 0,1 g/l CaCl2 x H2O, 1,16 g/l MgCl2 x 6H2O, 1,15 g/l Na2HPO4 
x 2H2O in 950 ml dissolved in dd Water, autoclaved, stored at 
4°C 
Deficient PBS 
(without Ca and 
Mg Chloride) 
0,8 g/l NaCl, 0,2 g/l KCl, 0,2 g/l KH2PO4 x H2O, 1,15 g/l 
Na2HPO4 x H2O in 950 ml dissolved in dd Water, autoclaved, 
stored at 4°C  
PBS++ 950 ml deficient PBS with addition of 50 ml Ca/Mg solution 
3.1.8 Media and buffers for cell culture 
Freezing medium for 10% (v/v) DMSO in FBS 
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cryopreservation of cells 
Fetal Bovine Serum (FBS) PAA Laboratories 
Penicillin/Streptomycin 
500X 
50.000 UI/ml Penicillin G, 50 mg/ml 
Streptomycinsulfat; dissolved in Aqua dd; sterile 
filtered (0,2 µm), and stored in 10 ml aliquots at -
20°C  
Amphotericin 500X 1.25 mg/ml (100 mg / 80 ml) dissolved in Aqua dd; 
sterile filtered (0,2 µm) and stored in 10 ml aliquots 
at -20°C 
Trypan blue 0,25% (w/v) Trypan blue, 0,15 M NaCl in Aqua dd, 
filtered (0,2 µm), and stored at 4°C  
Trypsin Solution 8 g/l NaCl, 0,2 g/l KCl, 1,44 g/l Na2HPO4 x 2H2O, 
2,5 g/l Trypsin, 1:300, 0,16 g/l Red Phenol dissolved 
in dd water, sterile filtered (0,1 Mm), and stored at 
4°C  
Cell Culture Medium CCM-
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4,5 g/l DMEM-Powder, 200 µM L-Alanin, 225 µM L-
Aspartat, 933 µM Glycin, 510 µM L-Glutamat, 217 
µM L-Prolin, 184 µM Hypoxanthin, 0,1 mg/l Biotin, 44 
mM NaHCO3, sterile filtered, store at 4°C 
Maintenance Medium  Cell Culture Medium, 10% FCS, 1 ml Penicillin 
(500X), 1ml Streptomycin (500X) and 1 ml 
Amphotericin (500X) 
3.1.9 Buffer for reverse transcription (RT) and polymerase chain reaction (PCR) 
PCR Water (Roth) double de-ionized water 
Buffer VIIIA (2,5 x) 125 mM Tris (pH 8,3), 187,5 mM KCl, 7,5 mM 
MgCl2, 25 mM DTT,  
1,25 mM dNTPs; -20°C 
Buffer VIIIB (5 x) 25 mM Tris (pH 8,3), 100 mM KCl, 6,5 mM MgCl2, 
1,25 mM dNTPs, 0,5% Triton X 100, 0,1% BSA; -
20°C 
TE-Buffer 10 mM Tris-HCl, 1 mM EDTA, in Aqua dd diluted, 
pH 7,6 
10 x PCR-Puffer NatuTec 
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Gel loading solution  Orange G: (0,25%) 2,5 ml Orange G 1%, 3,0 ml 
Glycerin, 4,5 ml H2O 
DNA loading buffer for agarose gels: 
0,1% (w/v) Orange G, 5% (w/v) Ficoll 400 in 5 x TAE 
buffer, 4°C 
100bp DNA ladder Invitrogen 
1kb DNA ladder Invitrogen 
Rothiphorese® 50x TAE 
Buffer 
Roth 
Deoxynucleoside 
Triphosphate Set PCR  
 
Roche 
3.1.10 Solutions for DNA cloning 
LB Medium 10 g/l Bacto-Trypton, 5 g/l Hefeextrakt, 8 g/l NaCl, 
dissolved in Aqua dd , pH 7,5 (with NaOH), 
autoclaved, stored at 4°C 
LB Medium Ampicillin 500 ml LB-Medium, 100µg/ml Ampicillin  
LB Medium Kanamycin 500 ml LB-Medium, 100µg/ml Kanamycin 
SOC Medium 2% Trypton, 0,5% yeast extract, 10 mM NaCl, 2,5 
mM KCl, 10 mM MgCl2, 10 mM MgSO4, 20 mM 
Glucose 
X-Gal Solution 40 mg/ml X-Gal (5-bromo-4-chloro-indolyl-
galactopyranoside), dissolved in DMF 
(Dimethylformamid) 
3.1.11 Solutions for SDS PAGE and PAGE-staining  
Semi Dry Blot Buffer 14 µg Glycine, 3.7µg Tris, 200 ml methanol (for 1 litre)  
4 x Protein Loading 
buffer 
250 mM Tris-HCl pH 6,8, 8% (w/v) SDS, 6 M Urea, 0,004% (w/v) 
Blue Bromphenol, 0,004% (w/v) Red Phenol, 40% (v/v) Glycerin, 
filtered, stored in 4 ml Aliquots at -20°C .  
for reducing conditions: add 5% (v/v) 2-Mercaptoethanol or 
10mM DTT. 
10% Jagow-Mini Gel 
separating gel 
2,5 ml acrylamide, 3,3 ml Jagow-gel buffer, 3,6 ml Aqua dd, 0,5 
ml Glycerine 87%, 50 µl APS 10%, 5 µl TEMED 
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4% Jagow-Mini Gel 
separating gel 
1 ml acrylamide, 2,5 ml Jagow gel buffer, 6,4 ml Aqua dd, 80 µl 
APS 10%, 10 µl TEMED 
10 x Anode buffer 2 M Tris-HCl, pH 8,9 
10 x Cathode buffer 1 M Tris-HCl, 1 M tricine, 1% SDS, pH 8,25 
Coomassie staining 
solution 
2,5 g Serva Blue, 454 ml methanol, 92 ml glacial acetic acid, fill 
up to 900 ml, then add 100 g of Trichloroacetic acid (TCA)  
Coomassie 
destaining solution 
10% (v/v) acetic acid, 30% (v/v) methanol in Aqua dd 
1 M NaCl in PBS++ 58,44 g NaCl in 1l PBS++  
SeeBlue® Plus2 Pre-
Stained Standard 
Invitrogen 
Western Lightning® 
Chemiluminescense 
Reagent Plus 
Perkin Elmer 
3.1.12 Buffers for protein purification (500 ml) 
Table 9: Preparation for the different buffers (FPLCA, FPLCB, FPLCA-urea, FPLCB-urea and FPLC lyse) used 
for protein purification. The values in () indicates the amount which should be add on the buffer to produce 
500 ml. 
Buffer Protocol 
FPLCA 300 mM NaCl (8.77 g), 50 mM Na2 HPO4 (4.45 g) 
FPLCB 300 mM NaCl (8.77 g), 50 mM Na2 HPO4 (4.45 g), 500 mM Imidazol 
(17.02 g) 
FPLCA 
urea 
8M Urea (240.2 g), 300 mM NaCl (8.77 g), 50 mM Na2 HPO4 (4.45 g) 
FPLCB 
urea 
8M Urea (240.2 g), 300 mM NaCl (8.77 g), 50 mM Na2 HPO4 (4.45 g), 
500 mM Imidazol (17.02 g) 
FPLC lyse 300 mM NaCl (8.77 g), 50 mM Na2 HPO4 (4.45 g), 1% Triton X-100 (5 
ml) 
3.1.13 Consumables 
Filter paper Whatman 
Cell culture plates Falcon 
Cell culture bottles  Falcon 
Gloves (Rotiprotect® Latex und Nitril) Roth 
Pipette Tips Biozym 
RNAse free pipet tips  Kisker Biotech 
Polypropylene tubes Eppendorf  
X-films BioMaxMR Kodak 
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0.22 µl and 0.45 µl sterile filters Fisher 
500 ml 0.22 µl filter Nalgene – Thermo 
Scientific 
3.1.14 Instruments and equipment 
Analytical balance Sartorius 
Bacteria Shaker  Heraeus 
Cell Culture Incubator (with CO2)  Forma Scientific  
Digital printer Sony 
X-ray developer machine  Protec 
Freezers Liebherr, Bosch 
Refrigerators Liebherr 
One channel pipette 2 µ, 10 µl, 20 µl, 200 µl, 1000 µl Biohit, Gilson 
Gel eletrophoresis chamber Institute of Virology, 
Gießen/Bio-Rad 
Gel Chambers Institute of Virology, 
Gießen 
Combs Institute of Virology, 
Gießen 
Gel documentation printer Mitsubishi – Intas 
Nanovue plus GE Healthcare Life 
Sciences 
Centrifuge Kendro Megafuge 1,0R Heraeus 
Centrifuge (4°C) Biofuge Fresco Heraeus 
Centrifuge (without cooling) Biofuge 13 Heraeus 
PCR cabinet Lamin Air/PCR Mini Typ HVPCR Holten 
Cell Culture Microscope Zeiss 
Heat block Institute of Virology, 
Gießen 
Minishaker MS1 (Vortex)  IKA 
Water bath Memmert GmbH & Co. 
KG 
Termocycler  Applyed Biosystems 
Realtime  Applyed Biosystems 
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Laminar Flow Thermo Scientific 
UV light box Bachofer 
3.1.15 Oligonucleotides  
Primers were both collected from selected publications or designed using 
PrimerExpress® (ABI). For design primers were based on an alignment of complete 
HEV sequences containing all different HEV genotypes and subtypes available at that 
time. Degenerated primers were designed using IUPAC symbols (table 10). Primer 
storage concentration was 50 pmol/µl. 
Table 10: IUPAC Symbols for degenerated bases. 
Description Bases Description  Bases 
R= A+G Y= C+T 
M= A+C K= G+T 
W= A+T S= G+C 
H= A+T+C D= G+A+T 
B= G+T+C V= G+A+C 
N= A+T+G+C   
3.1.15.1 Diagnostic 
For the molecular diagnostic of HEV different primers were employed, either self-
designed or from literature. Primers F1, R1, F2 and R2 amplify regions of 404 b and 266 
b, respectively, of the ORF2 region. (Lee et al., 2007; Meng et al., 1998). All primers 
used are described in the tables below. 
3.1.15.2 Literature 
Table 11: Primer used for HEV detection extract from the literature. 
Primer Name  Sequence  Reference 
 1st round: 404 bp; 2nd round:266 bp (Lee et al., 2007; Meng 
et al., 1998c) 
F1 AGCTCCTGTACCTGATGTTGACTC  
R1 CTACAGAGCGCCAGCCTTGATTGC 
F2 GCTCACGTCATCTGTCGCTGCTGG 
R2 GGGCTGAACCAAAATCCTGACATC 
  1st round: 730 bp; 2nd round:347 bp (Meng et al., 1997b) 
3156-EF AAYTATGCMCAGTACCGGGTTG  
3157-ER CCCTTATCCTGCTGAGCATTCTC 
3158-EF GTYATGYTYYGCATACATGGCT 
3159-IRS AGCCGACGAAATYAATTCTGTC 
  1st round: 197 bp; 2nd round:145 bp (Erker et al., 1999) 
HEVORF2con-s1 GACAGAATTRATTTCGTCGGCTGG   
HEVORF2con-a1 CTTGTTCRTGYTGGTTRTCATAATC 
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HEVORF2con-s2 GTYGTCTCRGCCAATGGCGAGC 
HEVORF2con-a2 GTTCRTGYTGGTTRTCATAATCCTG 
3.1.15.3 Self-designed 
Table 12: Self-designed primers for HEV detection. 
Primer name Sequence 
 1st round: 142 bp; 2nd round: 90 bp 
HEV01F TATGYTGCCCGCGCCA 
HEV01R AAAGGGGTTGGTTGGATGAA 
HEV02F CCGGYCAGTCGCCTGG 
HEV02R GCGAAGGGCTGAGAATCAAC 
 1st round: 191 bp; 2nd round: 143 bp 
Avian-1F GCTCATGCTTGCWATGTGCTGC 
Avian-1R TCTACATCTGGTACCGTGCGAGT 
Avian-2F GTGTCAAGGGGCTCCCAAAC 
Avian-2R ACCTGCCGCGGTGACAAC 
3.1.15.4 Sequencing 
Table 13: Primers designed for amplify the complete ORF2 and ORF3 for sequencing. 
Primer name Sequence Amplicon size  
ORF2/3 
HEVcF1 GTTGCGCAGGTTTGTGTTGA 591 bp 
HEVcR1 CCACGTGAATCTACATCAGGTACAG 
HEVcF2 CGGTCCTGCTCRTGTTGGTT 551 bp 
HEVcR2 AGAAGCCCCAGTGCACCA 
HEV7F TGAGACCTCTGGTGTGGCBG 570 bp 
HEV7R CGGTCCTGCTCRTGTTGGTT 
HEV1306F TCCCGCGTGGTTATTCAG 678 bp 
HEV1983R TTAAGACTCCCGGGTYTTACCTA 
Table 14: Self-designed primers for amplify the complete ORF 1. 
Primer name Sequence Amplicon size  
ORF1 
orf1HEV-1F ATGGTGGAGAAGGGHCAGGA  871 bp 
orf1HEV-1R ATCAACACAAACCTGCGCAACA 
ORF1-2F TGGTGGCACGTTACACACC 831 bp 
ORF1-2R TCTCCACCATGGCCTCAAC 
ORF1-3F ATGGAGGCCCATCAGTTCATTAA 974 bp 
ORF1-3R AGCATGAGCCGATCCCA 
ORF1-4F AAGGTGTATGCGGGGTCATTG 919 bp 
ORF1-4R AGCTCACACACATCAGCCGG 
ORF1-5F CTATATTTGGTCCTGGCGGC 842 bp 
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ORF1-5R GTCTTATTACCRAGCACAGTRCGGCACTC 
ORF1-6F ACTGTTGAACTCGTTGCAGG 938 or 820 bp 
ORF1-6R TGGTAAAAAGCATGGCAGAG 
HEV ORF1f2-R AGGTGTAGAGGAGACGACGA 
ORF1_2340F CGTAAGCCGTCAACACCCC 157 bp 
ORF1_2496R GACAGAGACCACCCCCGG 
3.1.15.5 Primers for sequencing 
Table 15: Primers for sequencing targeting M13 and T7 regions found into plasmid vectors (pCR2.1, pdrive 
and pET 26b). 
Name Sequence 
M13 Forward GTAAAACGACGGCCAG 
M13 Reverse CAGGAAACAGCTATGAC 
T7 Prom TAATACGACTCACTA   
T7 Term GCTAGTTATTGCTCA 
3.1.15.6 Expression 
Table 16: Primers designed for assembling selected regions of HEV ORF2 into the pET 26b+ vector. 
Primer name Sequence 
CapForBamHI GGATCCCGCCCTAGGGCTGTTCT 
Cap22ForBamHI GGATCCCACTATCGTAATCAGGGCTG 
CapRevHindIII AAGCTTGACTCCCGGGTTTTACCTACCTT 
expR4F GATCGACCGCGGAATGCTACTCCGTCACCTGCCC 
expR4R CTGCATGGATCCCGGGGTCGTCAGCAGTAT 
HEVexp-1180-F GATCGACCGCGGACAACTGTTTTACTCCCGCC 
HEVexp-827R CTGCATGGATCCAAGACTCCCGGGTTTTACCTA 
Cap21EXP-F GATCGACCGCGGTATGCGCCCTAGGGCTGTT 
Cap21EXP-R CTGCATGGATCCCAGAGCATTACCAGACCAGAAG 
Cap22EXP-F GATCGACCGCGGTATGCACTATCGTAATCAG 
Cap22EXP-R CTGCATGGATCCAGACTCCCGGGTTTTACCTA 
3.1.16 Real-time  
 For the PCR quantification a real-time assay was developed only for a specific 
strain (DQ996399) in order to evaluate the cell culture infection experiments. Probe (5’-
CCCGCCCGGTCGTCTCAGC-3’) and primers HEV-RT01F (5’-
GGCGAGCCGACTGTCAAGT-3’) and HEV-RT02R (5’-
CGTGTGGTATAGCAATGCCCTTA-3’) (Figure 6).  
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Figure 6: Specific primers and probes for sequence DQ996399. 
Another real-time assay was employed in order to evaluate the infection of both 
cell culture and primary hepatocytes with a different viral strain. Primers JVHEVF (5’-
GGTGGTTTCTGGGGTGAC-3’) JVHEVR (5’-AGGGGTTGGTTGGATGAA-3’) and probe 
JVHEVP (5’-TGATTCT CAGCCCTTCGC-3’) were extracted from the literature  
(Jothikumar et al., 2006). This was performed in CVI Lelystad, the Netherlands.    
3.2 Methods 
3.2.1 Nucleic acid extraction 
3.2.1.1 Sera, cell supernatants and fecal suspensions 
Fecal samples were individually diluted at 1:10 PBS (1 g in 10 ml) and shaken for 
15 minutes at room temperature. After that samples were centrifuged at 4000 RPM 
(2772 x g) for 10 minutes at 4 °C the supernatants were collected and stored at -20 °C. 
RNA was extracted from 140 µl of fecal suspension (swine), sera and cell supernatant 
using the QIAamp Viral RNA Mini Kit (Qiagen®) following the manufacturer’s 
instructions.  
This kit is based on the principle of the RNA binding to the silica membrane. 140 
µl of serum and cell or fecal suspension were added to 560 µl lysis buffer (AVL) 
containing 5.6 µl RNA carrier and incubated for 10 minutes at room temperature. This 
step is necessary in order to inactivate the RNAses and to ensure the isolation of pure 
RNA. The presence of the RNA carrier improves the binding of the RNA to the 
membrane, which is especially important when dealing with samples with low amount of 
RNA. After the incubation time 560 µl of ethanol was added, the mixture carefully 
pipetted and applied to the columns containing the silica membrane (QIAamp mini spin 
Column, Qiagen®). Afterwards a centrifugation at 6000 x g (8000 RPM) for 1 minute 
was performed, followed by two washing steps with buffers AW1 and AW2 (8000 RPM 
for 1 minute and 14000 RPM for 3 minutes, respectively). For elution 50 µl of AVE buffer 
was added and incubated for at least 1 minute. Columns were centrifuged for 6000 x g 
for 1 minute and RNA stored at -20°C until use. 
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3.2.1.2 RNA extraction from cultivated cells 
RNA was extracted using RNeasy kit (Qiagen) following manufacturer’s 
instructions. Cell supernatants (cell culture medium) were removed from each well of the 
plate and cells were re-suspended directly with 600 µl of lysis buffer (RTL). The lysate 
were shortly whirled with a vortex and displaced in the QIAshredder column and 
centrifuged for 2 min at full speed. One volume of ethanol 70% (600 µl) was added to 
each homogenized lysate cells solution and mixed with pipette. It was than displaced in 
the RNeasy spin column (up to 700 µl) and centrifuged for 15 seconds at 10000 RPM. 
The flow-through was discarded and each column was washed with 700 µl of RW1 
buffer, again followed by centrifugation for 15 s at 10000 RPM. The columns were 
washed two times with 500 µl of RPE buffer and centrifuged for 15 s and 2 min, 
respectively, at 10000 RPM. Column was disposed in a fresh 1.5 polypropylene tube 
(Eppendorf®) and RNA was eluted with 50 µl of RNAse free water placed directly to the 
spin membrane. After incubation of 1 min column was centrifuged for 1 min at 10000 
RPM. RNA was stored at -20°C. 
3.2.1.3 DNA extraction/purification 
3.2.1.3.1 Phenol-chloroform method.  
Before starting it is important to emphasize that with this technique it is desirable to 
work with large amount of DNA (> 5 µg). In addition the safety recommendation to work 
with phenol and chloroform should be followed. 
One volume of Phenol (100-400 µl) was added to the sample and mixed by carefully 
inverting the tube several times followed by centrifugation for 4 minutes at 13000 RPM. 
The formation of two phases should be observed and the upper phase collected and 
pipetted in a fresh tube. 
One volume of Chloroform was added and centrifuged (4 min/13000 RPM). 
Afterwards the upper phase was collected and disposed in a new tube. 1 ml of 100% 
Ethanol was added and centrifuged. Carefully the supernatant was discarded, 70% 
Ethanol added and the tube centrifuged. Lastly the supernatant was discarded and the 
DNA carefully eluted using 50 µl of RNAse free water. 
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3.2.2 Nucleic acid amplification 
3.2.2.1 Reverse transcription polymerase chain reaction (RT-PCR) 
3.2.2.1.1 Reverse transcription 
In the reverse transcription the RNA will be transformed into DNA with the use of 
the enzyme reverse transcriptase. First a master mix was prepared using RNAse free 
water and reverse primer in a 0.2ml tube. RNA template (2.5 µl) was added to 9 µl of the 
start mix and denaturized for 3 min at 94º. After cooling down to 4°C and 8.5 µl reverse 
transcriptase mix was added and incubated for 30 minutes at 45ºC and 80ºC for 2 
minutes (table 17). At the end of the reaction cycle the mixture was chilled at 4° C. 
Following the RT-PCR program described on table 19. 
 
Table 17: Reagents and protocol for reverse transcription. 
Start mix Reverse transcription mix 
8.5 µl H2O 8 µl Buffer A 
0.5 µl reverse primer 0.25 µl Reverse transcriptase 
 0.25 µl RNAse inhibitor  
9 µl 8.5 µl 
3.2.2.1.2 Polymerase chain reaction (PCR) 
The PCR is a molecular technique to amplify copies of a certain DNA fragment. It 
consists in several cycles of denaturation, annealing and elongation. After DNA 
denaturation to separate the double strand, the primers will bind or anneal to a specific 
region in the DNA at a determined temperature. Afterwards with aid of taq polymerase 
enzyme the second DNA strand will be synthesized complementary to the first strand. 
These three steps will be repeated several times (cycles) in the interest of increase the 
amount of DNA molecules.  
After the reverse transcription 30 µl of the PCR mix were added to the 0.2ml tube 
containing the cDNA. Following, a nested PCR was performed using another PCR mix 
(table 18). For the nested PCR 2.5µl of the HEV PCR reaction was added into 47.5µl of 
the nested PCR reaction mix (table 18) and following the HEV nested program 
described on table 19.  
Table 18: Protocols for PCR after reverse transcription and nested-PCR. 
Amount Reagent 
  PCR 
0.5 µl x n Primer HEV-F1  
10 µl x n Buffer VIIIb 
19.3 µl x n Aq dd 
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0.2 µl x n Polymerase 
Nested 
0.5 µl x n Primer  HEV-F2 
0.5 µl x n Primer  HEV-R2 
5 µl x n Buffer 10X 
0.4 µl x n dNTP-Mix 
0.2 µl x n Polymerase 
40.9 µl x n Aq dd 
3.2.2.1.2.1 PCR programs 
Table 19: PCR programs employed for amplification of HEV RNA. 
Name Denaturation Annealing elongation Cycles  
HEV PCR 94°C /30 sec 55°C/30 sec 72°C/30 sec 40 
HEV NESTED 94°C /30 sec 55°C/30 sec 72°C/30 sec 40 
3.2.2.2 OneStep RT-PCR 
For the OneStep RT-PCR (Qiagen) a ready to use PRC setup was perfomed 
according to the manufacturer instructions adding 0.25µl of RNase inhibitor in each 
reaction (table 20) plus 0.6 µl of each primer (50pmol). Each setup has been performed 
according to the PCR programs described on table 21. 
Table 20: Protocol for OneStep RT-PCR. 
Amount Reagent 
10.0 µl x 5x QIAGEN OneStep RT-PCR Buffer 
2.0 µl x dNTP Mix 
2.0 µl x QIAGEN OneStep RT-PCR Enzyme Mix 
0.25 µl x RNase inhibitor 
29.55 µl x RNAse free water 
 
 
Table 21: Different PCR programs employed in the amplification of HEV RNA using the OneStep kit. 
Region Denaturation Annealing elongation Cycles  Amplico
n size 
Capsid (ORF 2 and ORF 3) 
R1 94°C /1 min 57°C/30 sec 72°C/1 min 40-45 590 
R2 94°C /30 sec 56°C/30 sec 72°C/1 min 40 550 
R3 94°C /30 sec 55°C/30 sec 72°C/1 min 40 570 
R4 94°C /30 sec 55°C/1 min 72°C/1 min 40 677 
ORF2.1 94°C /30 sec 54°C/1 min 72°C/1 min 40 843 
ORF2.2 94°C /30 sec 55°C/1 min 72°C/1.3 min 40 1230 
ORF 1 
ORF1-A 94°C /30 sec 54°C/30 sec 72°C/1 min 40 871 
ORF1-B 94°C /30 sec 54°C/30 sec 72°C/1 min 40 831 
ORF1-C 94°C /30 sec 54°C/30 sec 72°C/1 min 40 974 
ORF1-D 94°C /30 sec 55°C/1 min 72°C/1 min 40 919 
ORF1-D2 94°C /30 sec 55°C/1 min 72°C/1 min 40 862 
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ORF1-E 94°C /30 sec 56°C/30 sec 72°C/1 min 40 842 
ORF1-F 94°C /30 sec 53°C/1 min 72°C/1 min 40 938 
ORF1-F2 94°C /30 sec 54°C/1 min 72°C/1 min 40 820 
ORF1-F3 94°C /30 sec 58°C/30 sec 72°C/30 sec 40 157 
3.2.2.3 Real time PCR 
The reverse transcriptase real-time PCR (qRT-PCR) was performed in two steps. 
First a HEV cDNA was produced and then the qPCR was completed (table 22). 5 µl 
RNA was added to 14 µl of A-mix aliquot then it was heated to 94 °C for 3 min. The 
tubes were rapidly chilled on ice and stayed there for at least 2 min. Afterwards 19 µl 
(RNA + A-Mix) were added to 81µl of RT-mix (B-Mix) and incubate for 30 min at 45 °C, 
followed by 2 min at 94 °C. After that the tubes were directly placed on ice. For the real-
time 2 µl of cDNA was added to 18 µl of the real-time mix samples (table 22). First 
samples were denatured for 20 s at 95°C, than 40 cycles (1 s 95°C, 20s 60°C, 15 s 
72°C). Samples were performed in duplicate or triplicate wells.  
 
Table 22: Reagents mix used in the real-time assay. 
Amount  Reagent  
A-Mix 
1 Primer RT02R 
13 RNAse free water 
B-Mix 
40 2.5x PCR buffer 8a 
0.5 RNAse Inhibitor 
0.5 Superscript RT 
40 aq dest 
Real-time mix 
10 TaqMan Fast Master Mix 
0.4 Primer RT-01F  
0.4 Primer RT02R  
1 HEV SondeTaq (Sonde 5 µM) 
6.2 aq dest 
3.2.3 Analysis of PCR products by agarose gel electrophoresis 
For gel preparation 1.5% gels were used (agarose powder dissolved in TAE 
buffer). For a more accurate visualization the concentration of agarose was adjusted 
according to size of the expected fragment (table 23). 
Table 23: Scheme for load different DNA fragment sizes into agarose gels. 
Size Agarose concentration (%) Voltage Duration 
Small (<100 b) 2.5 -3 %  100 35 min 
Standard (100 b – 1 kb) 1.5% 100 35 min 
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Large (>1 kb) 0.8 – 1% 60-90 40-60 min 
 
Electrophoresis chamber was filled with TAE buffer containing 0.01% etidium 
bromide. 8 µl of PCR product was mixed with 2 µl of loading buffer and 8 µl added in 
each slot. Electrophoresis was performed for 35 min at 100 V using 400 mA (for other 
voltages and durations see table 23). Gel fluorescence was photo-documented through 
an UV light transilluminator. 
3.2.4 Gel extraction 
PCR bands and enzymatic reactions were excised in the desired size from the 1, 
1.5 or 2% agarose gels. They were weighted and purified using QIAquick or QIAEX Gel 
extraction kits (Qiagen) following the manufacturer`s recommendations. 
3.2.5 Cloning 
3.2.5.1 Ligation and transformation  
3.2.5.1.1 PCR products 
PCR products were ligated to the vectors pCR®2.1-TOPO® (Invitrogen) or pDrive 
(Qiagen®) and transformed into E. coli TOP 10 (Invitrogen) or Qiagen EZ (Qiagen®) 
chemically competent cells. Cells were plated in LB medium with Ampicillin with addition 
of 40 µl X-Gal in order to perform blue/white selection. The plates were incubated 
overnight (at least 16 hours). For each sample five to seven white colonies were picked 
and grown overnight in tubes containing 3 ml LB medium with ampicillin.  
3.2.5.1.2 pET 26b (+) vector 
First the pET26b (+) vector with ubiquitin was linearized using the BamHI and 
SacII restriction sites. After the control digestion the linearized vector ends were zipped 
using alkaline phosphatase at 37° for 30 min. The reaction was placed on an agarose 
gel and the linear vector (band) excised from the gel and purified using the Qiaquick 
extraction kit (Qiagen). 
For the ligation approximately 100 ng of vector and 0.2 pmol of insert were used 
in a 20µl reaction mix. 
3.2.6 Plasmid preparation 
DNA was extracted from plasmids using the QIAprep Spin Miniprep kit (Qiagen). 
Two ml from each of the bacterial culture were centrifuged with 5000 RPM for 10 
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minutes at 4°C. Bacteria pellets were re-suspended gently using 250 µl P1 buffer. 
Afterwards 250 µl buffer P2 was added and the tubes inverted thoroughly but gently for 
approximately 10 times. The neutralization buffer (N3) was added and the tubes inverted 
again 10 times followed by centrifugation at 13000 for 10 minutes. The supernatants 
were displaced in the silica columns and centrifuged for 1 minute. Silica membranes 
were washed with 500 µl and 750 µl of buffers PB and PE, respectively. DNA was eluted 
with 50 µl of elution buffer (EB), incubated for 1 minute and centrifuged for 8000 RPM.  
Plasmid DNA samples were immediately digested using restriction enzymes in 
order to control the presence and the size of the insert. Control digestion was performed 
using Eco RI in both ends of the insert for both pDrive and pCR®2.1-TOPO. 2 µl of 
plasmid DNA was added to 8 µl of the digestion mix (Table 24) and samples incubated 
for 37°C during 90 minutes. After that 4 µl of the loading buffer was added to the 
restriction mix and placed on the agarose gel.  
Table 24: PCR-Clonning-vector digestion using restriction sites. 
Reagent µl 
H2O 5.8 
Eco RI Buffer 1.0 
BSA 1.0 
Eco RI 0.2 
Total 8.0 
3.2.7 Sequencing  
Table 25: Several bioinformatic softwares used for different purpose. 
Software Description/Us
e 
Manufactured/
Developed  
Available at 
Primer 
Express 2.0 ® 
Primer design Applied 
biosystems 
www.appliedbiosystems.com 
HUSAR  Bioinformatic 
package  
DKFZ 
Heidelberg 
http://genome.dkfz-
heidelberg.de/ 
MEGA 
4(Tamura et 
al., 2007b) 
 
MEGA 
5(Tamura et 
al., 2011) 
Molecular 
Evolucionary 
and genetic 
analysis 
Koichiro 
Tamura, Daniel 
Peterson, 
Nicholas 
Peterson, Glen 
Stecher, 
Masatoshi Nei 
and Sudhir 
Kumar  
http://www.megasoftware.net/ 
TreeView 
1.6.6 
Phylogenetic 
tree drawing  
University of 
Glasgow 
www.taxonomy.zoology.gla.ac.uk/ro
d/treeview.html 
RDP 3(Martin 
et al., 2010) 
Recombination 
detection  
Darren Martin http://darwin.uvigo.es/rdp/rdp.ht
ml 
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After fragments were checked to be in the expected size, plasmid DNA samples 
were sent for sequencing to Qiagen (Hilden, Germany) or Seqlab (Göttingen).  
3.2.8 Phylogenetic analysis  
Phylogenetic analysis was performed using the HUSAR package (DKFZ, 
Heidelberg). Sequences were compared to GenBank entries and phylogenetic analyses 
performed using the HUSAR package. Phylogenetic distances were calculated (Kimura-
2-parameter method) and trees generated based on the neighbor-joining or the 
maximum likehood methods. A bootstrap analysis with 1000 replicates was included. 
Branch lengths are proportional to genetic distances. Additional analyses such as 
detection of viral recombination and antigenicity prediction were performed using 
different softwares (or bioinformatics packages) which can be seen in table 25. 
3.2.9 Protein Purification 
3.2.9.1 Test expression 
Bacterial colonies were inoculated in 1 ml LB-KAN medium and let grown 
overnight (16 h) at 37°C. In next morning 0.5 ml of the bacterial culture was placed in a 
fresh tube and induced with IPTG (2 µl) for 4-5 hours at 37°C (shaking); together with 
the non-inducted cells. 
After the incubation 1 volume of non-inducted and 2 volumes of inducted cells 
were collected and centrifuged at 4000 RPM for 15 minutes. Supernatants were 
discarded and the pellets dissolved in approximately 15 µl of water each. 5 µl of 4xVD 
buffer was added to the samples and incubated for 5 minutes at 95°C. 
3.2.9.2 Expression for purification 
1ml of bacterial culture was added in 250 ml LB-KAN medium and incubated 
overnight at 37°. One aliquot was collected and the cells were inducted with IPTG (250 
µl) during 4-5 hours at 37°C. Bacterial cultures were centrifuged at 3000-4000 RPM for 
approximately 15 minutes. Supernatants were discarded and bacterial pellets were lysed 
using lysis buffer and three times freeze in liquid nitrogen and thaw with ultrasound. 
Splits Tree 
4(Huson and 
Bryant, 2006) 
Phylogenetic 
Analysis 
Daniel Huson 
and David 
Bryant 
http://www.splitstree.org/ 
SimPlot (Lole 
et al., 1999) 
Recombination 
detection  
Stuart Ray http://sray.med.som.jhmi.edu/SC
Roftware/simplot/ 
IEDB Analysis 
Resource 
Antibody epitope 
prediction 
 http://tools.immuneepitope.org/to
ols/bcell/iedb_input 
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Lysed bacteria were transferred to an ultracentrifuge (UC) tube, carefully closed 
and weighted. UC tubes were centrifuged at 30.000 RPM for 1 hour at 4°C using Rotor 
TIC60. 
3.2.9.3 Purification using Columns 
3.2.9.3.1 Western blot was performed using both supernatants and pellets: 
(a) Protein detected in the supernatant: protein is soluble and can be directly purified 
using Ni-Column (using buffer without urea: FPLCA + FPLCB) 
(b) Protein can only be detected in the pellet: protein is insoluble and should be 
solubilized overnight using in FPLCA + Urea (8 M). After that it is (ultra-) 
centrifuged or sterile filtered (0.45 µm filter) one more time. Subsequently it can 
be purified using Ni-column (using buffers with urea: FPLCA urea + FPLCB urea). 
3.2.9.3.2 Running through the column: 
Before starting, it is important to prepare the peristaltic pump and test it properly. 
Note that air bubbles may break the column. 
(1) Wash the column with FPLCB (approximately 10 ml). 
(2) Equilibrate the column with FPLCA buffer (approximately 10 ml). 
(3) Load up the column with the protein slowly and continuously; approximately 0.75-
1 ml/min. This step can be repeated 2-5 times. 
(4) Wash the column with 1x FPLCA buffer (approximately 10 ml). 
(5) Elute the protein using FPLCB buffer with different imidazole concentration, each 
aliquot of about 5ml. 
a. 50 mM imidazole 
b. 100 mM imidazole 
c. 500 mM imidazole (3 times) 
(6) Wash the column one more time with buffer FPLCB (approximately 10 ml) 
(7) Wash column with ddH2O (approximately 10 ml) 
(8) Load the column with ethanol 20%, close it and store at 4°C. It can be further 
used to purify other aliquots from the same protein. 
(9) Clean the pump tubes with water or ethanol 20%. 
Finally all protein eluted aliquot with different imidazole concentrations (E1–5) should 
be placed in an acrylamide gel. After electrophoresis the gel must be stained with 
commassie and it should be possible the see the band in the expected size and to 
choose which of the imidazole concentration is more suitable to be used further. 
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3.2.10 Working with cell culture 
3.2.10.1 Storage 
Cell lines (master seed or working seed cultures) were stored in liquid nitrogen. 
Each aliquot contained a number of cells necessary to be confluent in one to two days in 
a 10 cm dish. All cell lines plates (10cm, 6 or 24-well plates) used were under quality 
control management system. 
3.2.10.2 Passage and maintenance  
In order to estimate the viability cells were evaluated macro- and microscopically. 
Cell layer was detached using EDTA-trypsin solution and diluted to the desired 
proportion. The dilution factor was determined according to previous information of cell 
growing from each cell line as well as the level of confluence. 
Cells were maintained using medium with 10% FCS with penicillin, streptomycin 
and amphotericin and passaged twice a week. Old medium was removed and cell layers 
washed with the equal amount of EDTA-trypsin solution. Afterwards 1 ml of EDTA-
trypsin solution was added and plates were incubated until the cells were completely 
detached from the plate. Finally 9 ml maintenance medium was added and cells were 
placed in the new plates into the desired dilution. 
3.2.10.3 Determination of cell concentration 
Cell suspensions were used in order to determine the number of viable cells. This 
was performed by the use of the trypan blue exclusion test. The principle of this test is 
based on trypan blue characteristics: As soon as the cell membrane is undamaged the 
trypan does not enter in the cell; however, when the cell is dead the membrane can be 
traversed giving a strong blue coloration. For this 20 µl of cell suspension were diluted in 
180 µl of trypan blue solution. Live cells (without blue color) were observed in an 
inverted microscopy and counted in four big squares of a Fuchs-Rosenthal chamber 
(diagonale). The determination of the cell number was obtained by the following formula: 
n x 4 x V x 1000 = n of cells/ml 
           3.2 
(n= total of cells in the four squares, V= dilution factors) 
3.2.11 Infection of A549 cell line  
A549 cells were passaged and counted into a 24 well plate. The concentration of 
cells was around 1.2 x 106 cells/ml => 50µl/well = 6 x 103. A fragment of infected liver 
was cut and triturated with sterile sand and medium without FBS. The suspension was 
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centrifuged at 2700 g (3500 – 4000 rpm) for 10 minutes at 4°C. Supernatants were 
collected and sterile filtered (0.22 µl). Medium (containing 10% FBS) was removed and 
200 µl of medium without FBS was added. Cell layers were infected with 4 µl, 20 µl and 
100 µl of the suspension and incubated for 1h. Cell layers were washed with 1 ml of 
medium without FBS. Medium with 1%, 2%, 5% FBS and serum free medium with 
trypsin were added. Cells and supernatants were collected on days 0 (only supernatant), 
2, 4, 6, 8, 10, 12, 14.  
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4 Results 
4.1 HEV in domestic swine and wild boar  
4.1.1 Detection of HEV in domestic swine 
Hepatitis E is an emerging infectious disease distributed worldwide which occurs 
in both humans and animals such as domestic swine and wild boar. In contrast to the 
situation in humans, no clinical disease has been associated with HEV in animals so far, 
although sequences from human and animal HEVs are closely related and zoonotic 
transmission is known to take place. To elucidate the HEV prevalence in different animal 
populations of domestic swine and wild boar samples from Germany, The Netherlands 
and Morocco were tested for the presence of HEV RNA.  
A panel of fecal samples from 105 domestic swine was available which had been 
used in another study. A fragment of 241 nucleotides from the capsid gene region of the 
HEV genome was amplified in one out of 105 fecal samples (0.95 %). The animal, a four 
month old female Pietrain breed, originated from Giessen (Hesse state) and was 
clinically healthy. The negative animals originated from different regions of Germany and 
one Dutch farm. Information about age and sex, if available, is shown in Figure 7. 
 
Figure 7: Domestic swine sampling: age and sex distribution. Green: no 
information on sex available. X-axis: age, nn: no age given. 
 
4.1.2 Detection of HEV in wild boar 
Wild boar sera were provided by “Landesbetrieb Hessisches Landeslabor” and 
originated from the classical swine fever surveillance program. HEV could be detected in 
18 out of the 124 sera, corresponding to a detection rate of 14.5 %. The positive animals 
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were distributed in the sampling area (Fig. 8 and Table 26). No information about sex 
and age of the animals was available.  
Until now only few HEV strains have been detected in Africa. To elucidate the 
situation there, 160 wild boar sera were obtained from a farm in Morocco. The animals 
were kept semi-intensive fenced. None of these samples was positive by RT-PCR. All 
animals were apparently healthy. Age and sex distribution are listed in figure 9.  
 
Figure 8: Geographical distribution of wild boar samples tested (positive samples / total samples). Dark grey 
indicates were positive samples were found, light grey shows regions where samples were collected but no 
positive have been found. 
 
 
 
 
 
 
 
 
 
 
Figure 9: Age and sex distribution of wild boar in Morocco. 
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4.1.3 Phylogenetic analysis 
PCR fragments of 241 nt (capsid position: from nt 449 to 691) obtained from 
samples of domestic swine and wild boar were cloned, sequenced and phylogenetically 
analyzed. The level of divergence between the obtained sequences is given in table 27. 
The nucleotide differences (pairwise corrected distances) between the sequences from 
domestic pigs and wild boar ranged from 11.57 to 21.45 %. Within the wild boar 
sequences differences from 0 to 21.61 % were observed. 
The obtained sequences clustered in different branches within genotype 3 of HEV 
(Fig. 10). Bootstrap values were generally low (under 750), which denote a low reliability 
of the analysis. The wild boar isolates (WB122) and one sample from domestic swine 
(GiSw) grouped together with sequences from subtype 3a (AB074918 and AB089824). 
A second group comprising five isolates (WB69, WB117, WB120, WB121 and WB124) 
showed the closest relationship to sequences previously classified as subtypes 3a, 3j 
and 3b. The third group with the majority of our isolates clustered in subtype 3i together 
with German isolates (FJ998008 and FJ705359) and subtype 3h (AB290312) 
comprising a Mongolian swine isolate (Fig. 10 and Table 26). 
Table 26: Regions where positive wild boar samples were found; subtyping according to 241 b and 2.1 
kb; accession numbers 
 
Region 
N. 
pos 
Sample 
Identification 
Subtype Accession 
numbers 241b 2.1 kb 
Rheingau-Taunus-
Kreis 
2 
 
WB 1,  3i, 3h  3i KF303501 
WB 121 3a,3b, 3j  KF303496 
Wiesbaden 2 WB 22 3i  KF303486 
  WB 24 3i, 3h  KF303485 
Lahn-Dill-
Kreis/Wetzlar 
7 WB 25 3i  KF303494 
WB 75 3i  KF303489 
WB 76 3i  KF303490 
WB 104 3i  KF303493 
WB 119 3i  KF303491 
WB 117 3a,3b, 3j  KF303484 
WB 124 3a,3b, 3j  KF303498 
Marburg-
Biedenkopf/Lahn 
3 WB 34 3i, 3h  KF303487 
WB 91 3i  KF303488 
WB 122 3a 3a KF303499 
Waldeck-
Frankenberg 
1 WB 52 3i  KF303492 
Hochtaunuskreis 1 WB 69 3a,3b, 3j 3a KF303500 
Limburg 2 WB 118 3i  KF303495 
  WB 120 3a,3b, 3j  KF303497 
Total 18     
5
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4.1.4 Sequencing of the complete capsid gene and phylogenetic analysis of HEV 
from domestic swine and wild boar samples 
In order to broader the knowledge about the phylogenetic relationship of the 
obtained isolates the capsid protein was sequenced. For sequencing of the complete 
capsid gene (1983 nucleotides) of HEV in the samples from domestic swine and wild 
boar ORF 2 was divided into four regions named R1, R2, R3 and R4 (Fig. 11). R1 region 
corresponded to the 5’ end of the capsid protein encoding sequence together with 205 
nucleotides from the 3’ end of ORF1 (Fig. 11). It was intended to sequence the entire 
capsid region from several HEV positive samples. However due to limited amounts of 
samples, additional sequences were obtained only from three wild boar samples (WB1, 
WB69 and WB122) and the positive domestic swine (GiSw). 
 
Figure 11: Regions for sequencing of the entire capsid gene. ORF 2 was divided into four regions named R1 
to R4.  
Based on complete capsid sequences higher bootstrap values and a more 
reliable separation of subtypes could be achieved (Fig. 12). Accordingly GiSw, WB122 
and WB69 were placed into subtype 3a. The WB1 sequence clustered in one branch 
together with two previously reported viruses from wild boar in Germany classified as 
subtype 3i (FJ705359 and FJ998008) (Adlhoch et al., 2009b; Schielke et al., 2009). 
Pairwise comparison of the latter three sequences showed a remarkably high 
heterogeneity of 10.6 and 13.5 substitutions per 100 nucleotides, respectively. The 
heterogeneity within subtype 3i was thus much higher when compared with other 
subtypes; for instance within 3a, 3d and 3f (Table 28). 
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4.1.5 Search for recombinants  
Recombination among closely related RNA viruses is a common event. The high 
heterogeneity observed among wild boar sequences and the difficulties to classify 
subtypes unambiguously made the search for recombination promising. Different 
approaches can be used in order to detect recombination events and recombination 
sites. The split decomposition method which allows to show conflicting phylogenetic 
signals was applied first. This method can be used to show alternative positions of these 
sequences in a given phylogenetic tree by plotting parallel edges between them forming 
an interconnected network. Such a network means a conflict in the phylogenetic analysis 
may be due to recombination. In the second approach we used the recombination 
detection package 3 (RDP 3); this software combines a number of different 
recombination detection methods (Martin et al., 2010).  
The tree based on a 241 b fragment of the HEV capsid region was plotted using 
the split decomposition method. Conflicting phylogenetic signals on wild boar isolates 
were found (Fig. 13). The presence of a network instead of bifurcation connecting the 
isolates may indicate viral recombination. 
Analyses using the RDP 3 suggested recombination events with regard to six 
sequences. The first recombination event concerned isolate WB24 with isolate WB25 as 
potential major parent and WB34 as potential minor parent. The recombination 
breakpoints began at position 21 and ended at position 154. The second event 
concerned isolate WB121 with WB75 and WB117 as potential major and minor parents. 
The recombination breakpoint started at position 4 and ended on position 163.  
The graphical representation based on the PhylPro method is shown in Figure 
14A. The trees were constructed using different regions of the 241 b fragment. On the 
left side the region with possible recombination breakpoint was used (from 4 to 163) 
(Fig. 14 B); and on the right side the tree is based on the region where no recombination 
was detected (from 163 to 4) (Fig. 14 C). It is possible to observe some isolates shifting 
position (even subtype) on the different position-based phylogenetic trees (Fig. 14B and 
14C). Unfortunately it was not possible to obtain larger sequences from these isolates. It 
is unclear whether the recombination detected was a bias due to the fragment size or 
region or indeed due to the occurrence of recombination. 
6
2
 
 
 
F
ig
u
re
 1
3
: 
T
h
e
 p
lo
tt
e
d
 t
re
e
s
 s
h
o
w
 t
h
e
 n
e
tw
o
rk
s
 g
e
n
e
ra
te
d
 b
y
 s
p
li
t 
d
e
c
o
m
p
o
s
it
io
n
 s
u
g
g
e
s
ti
n
g
 a
lt
e
rn
a
ti
v
e
 p
o
s
it
io
n
s
 (
A
) 
c
o
m
p
a
ri
s
o
n
 w
it
h
 t
h
e
 t
re
e
 c
a
lc
u
la
te
d
 b
y
 t
h
e
 
n
e
ig
h
b
o
r-
jo
in
in
g
 m
e
th
o
d
. 
T
h
e
 B
ra
n
c
h
 l
e
n
g
th
s
 a
re
 p
ro
p
o
rt
io
n
a
l 
to
 t
h
e
 g
e
n
e
ti
c
 d
is
ta
n
c
e
s
 a
n
d
 b
o
o
ts
tr
a
p
s
 v
a
lu
e
s
 a
re
 i
n
d
ic
a
te
d
. 
.
A
 
B
 
63 
 
 
Figure 14: Search for viral recombination using PhylPro method (A) which shows where recombination 
may have occurred in the alignment. Phylogenetic trees show different positions of isolates WB75, 
WB117 and WB121 with the area where recombination possibly occurred 4 – 163 (C) and from 164 to 4 
(B). Phylogenetic trees are calculated by UPGMA method.  
A 
B C 
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4.1.6 Complete sequence of HEV isolate from domestic swine  
The complete genome of the GiSw HEV was amplified using a different set of primers. 
Subsequently, each fragment was cloned and sequenced. The ORF1 was divided into six 
overlapping regions, and primers were designed for each region (Table 29). In order to 
obtain the complete genomic sequence, ORF1 was assembled using the overlapping 
fragments and placed together with the ORF2/3 sequence (described previously) (Fig. 15). 
The genome of GiSw HEV consisted of three ORFs with a size of 5122 nt (ORF1), 1983 
nt (ORF2) and 369 nt (ORF3) flanked by 5’ and 3’ non-coding regions. The non-coding 
regions (NCR) from both 3’ and 5’ were not included in the sequencing. The encoding 
sequence was compared to genomic sequences obtained from GenBank, as shown in 
Figures 16 (genotype 3) and 17 (genotypes 1–5).  
Like deduced from other HEV complete sequences GiSw ORF1 encoded a polyprotein 
containing putative conserved domains: methyltransferase (MT) 34-355 aa, papain-like 
cystein protease (Pr) 432 – 592 aa, helicase (H) 980 – 1199 aa and RNA-dependent  RNA 
polymerase (RdRp) 1412 – 1594 aa. 
 
Figure 15: Genomic divisions used to sequence the domestic swine HEV GiSw. For sequening of the complete 
HEV genome, the genome was divided into overlapping regions. A – F: ORF1, R1 – R4: ORF2. 
Table 29: Primers for amplification of ORF1. 
Region Name Amplicon 
Size 
ORF1 A  orf1HEV-1F 871 
  orf1HEV-1R  
ORF1 B  ORF1-2F 831 
  ORF1-2R  
ORF1 C  ORF1-3F 974 
  ORF1-3R  
ORF1 D  ORF1-4F 919 
  ORF1-4R  
ORF1 E  ORF1-5F 842 
  ORF1-5R  
ORF1 F  ORF1-6F 938 
  ORF1-6R  
ORF1 F2 HEV ORF1f2-R 820 
ORF1 F3 ORF1_2340F 157 
 ORF1_2496R  
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Phylogenetic analysis demonstrated a close relationship between the GiSw and 
genotype 3 sequences. Pairwise genetic distances ranged from 9.88 to 26.35 % as can be 
seen in Table 30. GiSw clustered in a branch together with FJ426404 and FJ426403 found 
in Korean pigs, AF060669 and AF060668 from human patients from the US, AF082843 
found in domestic swine also from US and AB591734 in Mongoose in Japan (Fig. 16). 
Regarding to members of other HEV genotypes the number of substitution per 100 
nucleotides in the pairwise distance matrix was 32.7 from GT1, 32.1 from GT2, 31.0 from 
GT4 and 32.3 from GT 5 (Table 30).   
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4.2 Genetic variability in HEV isolates 1 
The International Committee on Taxonomy of Viruses (ICTV) does usually not 
consider classification below the specie level. The ICTV has defined four HEV genotypes 
and there is no official classification system for subtyping. Some research groups only use 
genotypes for classification (Sonoda et al., 2004; Takahashi et al., 2003; Tei et al., 2003; 
Wibawa et al., 2004), while others use one of the proposed subtyping systems. Arankalle 
and colleagues (Arankalle et al., 1999) suggested to divide genotype (GT) 1 into four sub-
genotypes (a, b, c and d), while Tsarev and coworkers (Tsarev et al., 1999) proposed one 
extra group (I2) in GT 1. Wang et al. (Wang et al., 1999) proposed to divide GT 1 in five 
groups and GT 3 into 2 groups; Schlauder and Mushahwar (Schlauder and Mushahwar, 
2001) divided GT1-4 into 11 independent subtypes. These systems were used to classify 
human strains at a time when few sequences from animal isolates were available. The most 
widely accepted system for subtyping of HEV sequences was published by Lu et al. (2006). 
This system placed the HEV sequences available at that time into 24 subtypes: GT 1(a-e), 
GT 2 (a,b), GT 3 (a-j) and GT 4 (a-g). Due to limited availability of sequence information the 
subtyping was based on both complete genomic and partial sequences from five different 
genomic regions. Complete genomic sequences were available for only few subtypes of 
genotype 3 (3a, 3b, 3g and 3j) and 4 (4c, 4d and 4g). In the meantime the number of HEV 
sequences has increased considerably from less than 10 complete sequences in the year 
1991 up to more than 90 in July 2012 (Fig. 18).  
4.2.1 Evaluation of the current system 
In our study three regions used by Lu et al. (2006) were reanalyzed and novel 
sequence information was added: ORF1 (first 287 nt 5’ end), ORF2 (301 nt of 5’ end and 
148 nt: 6390-6537). The use of these different genomic regions resulted in variable 
grouping of HEV isolates and did not allow a clear differentiation between certain subtypes. 
Furthermore, the respective phylogenetic trees were based on extremely low bootstrap 
values and did not allow a clear designation of subtypes (Fig. 19 A, B and C). For instance, 
using the region from ORF1 it was not possible to differentiate between subtypes 3i, 3h and 
3c as proposed by Lu et al. (2006); instead, all three were placed within a single branch. In 
                                                          
1
 Adapted from Oliveira-Filho  et al., 2013 
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addition the sequences classified as subtypes 3e and 3f by Lu et al. (2006) were placed 
into separate branches, but with very low bootstrap values (Fig. 19 A). Using one region of 
ORF2 (148 nt) it was not possible to differentiate between subtypes 3i, 3b, 3h as well as 
between 3e, 3f, 3g. Isolates representing these subtypes were mixed in two branches and a 
large number of potential new subtypes could be formed (Fig. 19 B). According to our data 
sequences previously classified as subtypes 4a and 4f by Lu et al. (2006) belong actually to 
one subtype within genotype 4 (Fig. 19 and 21). 
 
Figure 18: Number of complete HEV genomic sequences deposited in GenBank from 1991 to July 2012 (adopted 
from Oliveira-Filho et al., 2013). 
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4.2.2 Grouping of HEV based on complete genomic sequences  
As the next step HEV complete genomic sequences were used for phylogenetic 
analyses instead of partial fragments. It was expected that this approach would lead to a 
higher reliability of the analyses.  
Based on analyses performed here, the current HEV genomic sequences cluster into 
seven major branches, including established genotypes (GT) 1, GT 2, GT 4, three branches 
for GT 3 and a new branch formed by two wild boar isolates from Japan provisionally 
termed “GT 5” (Fig. 20 and 21). The maximum nucleotide differences observed within the 
established genotypes are 13.16 % (GT 1), 27.10 % (GT 3) and 19.96 % (GT 4); only one 
and two complete sequences are available for GT 2 and GT 5, respectively. Genotype 3 
showed a particularly high heterogeneity and could be separated into three subgroups, 
based on tree topology, nucleotide divergence and epidemiological features. Subgroup 3.1 
contains human and animal sequences from Asia (Japan, China, Korea, Mongolia), North 
America (USA, Canada) and Germany. Subgroup 3.2 comprises mainly sequences recently 
obtained from Europe, Japan, Thailand and one distantly related sequence from 
Kyrgyzstan. Subgroup 3.3 contains HEV sequences from rabbits farmed in China. 
Subdivision of GT 3 into three subgroups reduced the nucleotide divergence within the 
subgroups: 19.22 % (subgroup 3.1), 20.11 % (subgroup 3.2) and 18.01 % (subgroup 3.3). 
These values are comparable to the distances observed within genotypes 1 and 4 (Fig. 20). 
Our phylogenetic analyses support the idea that newly identified wild boar isolates from 
Japan form a novel separate genotype (“GT 5”). 
In comparison to GT 1 and 3, GT 4 showed a different pattern when the nucleotide 
divergence was compared. The spectrum of nucleotide distances between genomic 
sequences placed in GT 4 was narrow when compared to the other genotypes; this can be 
seen by the difference between the first (15.34 %) and the third (18.55 %) quartile (Fig. 20). 
Apparently most GT 4 sequences are equally distant to each other, pointing to a separation 
into sub-groups.  
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Figure 20: Box-and-whisker plots of nucleotide divergences within genotypes 1, 3 and 4. Note the decreasing 
level of heterogeneity when GT 3 is split into the subgroups 3.1, 3.2 and 3.3 (adopted from Oliveira-Filho et al., 
2013).
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4.2.3 HEV-like viruses  
Recently, HEV-like viruses have been identified in rats, bats and ferrets (Drexler et al., 
2012; Johne et al., 2010b; Raj et al., 2012). The genomic sequences of these viruses 
showed a high degree of divergence (64.03 – 81.21 %) when compared to the new 
Japanese wild boar isolates. When these sequences were compared to the isolates from 
the established HEV genotypes (1-4) on nucleotide basis, distances ranged from 27.11 to 
34.05 %. Our phylogenetic analysis together with sequences from HEV-like viruses clearly 
place Japanese wild boar virus within HEV as a new genotype (Fig. 22).  
Nucleotide distances ranged from 63.23 % to 81.60 % between viral sequences from 
rats, ferrets and bats compared to HEV GT1-4 (Table 31). Based on the phylogenetic 
analyses  recently discovered HEV-like viruses as well as avian HEV can be considered as 
new genera within the family Hepeviridae (Fig.  22).  
A virus found recently in cutthroat trout was claimed to be a member of the 
Hepeviridae family. This assumption was based in sequence analysis conserved motifs 
(helicase) (Batts et al., 2011). However, in our analysis using complete genomic 
sequences, the cutthroat trout virus (CTV) did not show a measurable degree of 
relatedness to HEV or the other members of the Hepeviridae (Table 31).
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Figure 22: Phylogenetic tree based on complete genomic sequences of HEV and HEV-like isolates. Colors indicate 
HEV genotypes: GT 1 green, GT 2 pink, GT 3 orange and GT 4 blue and GT 5 yellow. The tree was calculated by the 
neighbor-joining method. The branch lengths are proportional to the genetic distances. Bootstrap values of 1000 
replicates are indicated.  
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Table 31: Comparison between wild boar (GT 5), HEV-like viruses (found in rat, ferrets and Bats) and Cutthroat 
trout virus (CTV) to HEV (GT 1-4). Distances matrix based on complete genomic sequences. Values indicate the 
number of substitutions per 100 bases corrected by Kimura-2 parameter method. 
 GT 5  Rat  Ferrets Chicken Bats Fish 
Min 27.11 66.49 63.23 78.15 78.48 >100 
Mean 31.50 69.02 65.36 80.07 79.72 >100 
Max 34.05 71.05 67.63 82.71 81.60 >100 
4.2.4 Subtyping of genotypes 3 and 4 
The use of the complete capsid gene sequences instead of genomic sequences 
provided reliable phylogenetic trees and is considered adequate to classify available 
sequences into genotypes. The phylogenetic trees calculated either by the neighbor-joining 
or the maximum-likelihood methods led to similar topology (Fig. 23).  
Based on tree topology and pairwise nucleotide differences, GT 3.1 could be divided 
into three subtypes, GT 3.2 into three subtypes and GT 3.3 into two subtypes. However, the 
sequences within the groups showed high nucleotide divergence levels (up to 15.45 
%between 3.1, 3.2 and 3.3).  
In GT 4 several major branches were observed using both (Maximum-Likelihood and 
Neighbor-Joining) tree construction methods. However, acceptable bootstraps values were 
obtained only for three out of eight groups. Thus it was not possible to establish a reliable 
subtype classification comprising the majority of GT 4 isolates.  
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4.2.5 Geographic distribution  
The 187 complete HEV sequences analyzed in this study originated from 21 
countries in 4 continents. The majority of isolates (78.07 %) was from Asia with 92 (49.2 %) 
from Japan, 32 (17.11 %) from China and 7 (3.74 %) from India. More detailed information 
about the number and origin of samples is provided in table 32. GT 1 has only been found 
in Africa (Morocco) and Asia (Myanmar, China, Pakistan, India, Nepal), GT 2 in Mexico, GT 
3.1 in Asia (Japan, Korea and Mogolia), Europe (Germany) and North America (Canada 
and USA), 3.2 in Asia (Japan, Thailand, Kyrgyzstan and Mogolia) and Europe (France, 
Germany, Spain and Sweden), GT 3.3 (rabbit) only in China. Complete HEV genomic 
sequences of GT 4 is available only from Asia (Japan, China, India and Korea), however 
partial HEV sequences have been reported recently in Europe (Colson et al., 2012; Hakze-
van der Honing et al., 2011). We did not obtain any epidemiological evidence like 
geographical or host distribution to support further dissection of HEV into subtypes. 
Table 32: Geographic origin of the HEV complete genomic sequences. 
Continent Country Number (%) 
 
Genotype 
Asia Japan 92 49.20% 1,3,4,5 
China 32 17.11% 1,3,4 
India 7 3.74% 1,4 
Korea 3 1.60% 3 
Mongolia 2 1.07% 3 
Thailand 3 1.60% 3 
Kyrgyzstan 1 0.53% 1 
Pakistan 2 1.07% 1 
Nepal 1 0.53% 1 
Myanmar 2 1.07% 1 
  Taiwan 1 0.53% 4 
Africa Chad 1 0.53% 1 
America USA 6 3.21% 3,4 
  Mexico 1 0.53% 2 
  Canada 1 0.53% 3 
Europe Germany 8 4.28% 3 
  Spain 5 2.67% 3 
  France 4 2.14% 3 
  Sweden 1 0.53% 3 
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  Hungary 1 0.53% 3 
  UK 2 1.07% 3 
Cells  - 11 5.88%  
Total  187   
4.3 Expression of HEV capsid protein  
HEV capsid protein of the Gießen swine isolate (GiSw) was sequenced and its 
amino acid sequence was deduced. ORF2 with 1983 nucleotides encodes a capsid protein 
with 661 aa and a predicted molecular weight of about 71 kDa. Using different continuous 
linear B cell epitope prediction methods several immunogenic regions could be detected 
(Fig. 24). The HEV capsid protein contains several epitopes and immunodominant regions 
and thus is highly immunogenic. For instance a strong antigenic reactivity has been 
reported for aa 450 – 460, and an immunodominant region for aa 546 – 580 (Khudyakov et 
al., 1994). The region between aa 607 – 659 was the shortest fragment to be recognized by 
two neutralizing mAbs (Zhou et al., 2004).  
 
 
 
 
 
 
 
 
Figure 24: Prediction of epitopes for the GiSw capsid protein based on Chou & Fasman Beta-Turn (A), Emini 
Surface Accessibility (B), Karplus Schulz Flexibility (C), Kolaskar & Tongaonker Antigenicity (D), Parker 
Hydrophilicity (E) prediction methods. The red line shows the threshold, yellow and green colors have different 
meaning according to the method employed: A and C: score of antigenicity, B: score of surface 
probability,D:levels of antigenic propensity,E:  hydrophilicity.  
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4.3.1 Construction of recombinant capsid protein (ORF 2) in pET vector 
pET 26 (+) vector is a commercial vector from Novagen™ used to express proteins 
in the E. Coli system under control of the T7 promoter. The pET 26 plasmid was modified 
by insertion of ubiquitin to the encoding sequence in front of the multiple cloning site. 
Accordingly, foreign proteins are expressed as fusion proteins with ubiquitin at the N-
terminus and a poly histidine tag at the C-terminus. It was planned to express two different 
regions of the capsid protein namely aa position 1 – 278 in the N-terminal and a aa 543 – 
617 located in the C-terminal region (Fig. 25 and 26).  
 
Figure 25: Regions of HEV ORF2 expressed in E. coli. 
 
Figure 26: Strategy for construction of HEV Cap 2.1 and R4b recombinant vectors. 
For the amplification PCR was performed with the plasmid which contains the R4 
and HEV 2.1 regions. Primers were designed including SacII and BamHI restriction sites. 
The two different regions of the capsid protein in the N- and C-terminus were expressed 
using the pET vector, as can be seen in Figures 25 and 26.  
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4.3.2 Expression of the two capsid protein regions  
Western blot analysis of extracts from the bacterial cell pellets using anti–ubiquitin 
and anti–His-tag monoclonal antibodies (Mab) (Fig. 27) demonstrated the presence of the 
recombinant proteins detected in the expected sizes (Fig. 27).The fusion proteins showed  
estimated molecular weights of 17.2 kDa (Ubi-R4bHEVcap-His) or 38 kDa (Ubi-HEV 2.1-
His) (Fig. 27 and 28).  
 
Figure 27: Western blot of fusion proteins HEVcap2.1 (left) and R4b (right) using anti-ubiquitin monoclonal 
antibodies showing bands in the expected sizes. 
 
Figure 28: Western blot of fusion proteins R4b and HEVcap2.1. Reactivity with anti-His tag (A) and anti-ubiquitin 
(B) monoclonal antibodies. Note the presence of a double band in A and the presence of bands without IPTG 
induction. 
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4.3.3 Reactivity of fusion proteins  
Both proteins were successfully expressed and reacted with both the anti-ubiquitin 
and anti-His-tag monoclonal antibodies (Fig. 27 and 28). Expressed products were purified 
by ultracentrifugation and ion exchange chromatography using Ni-NTA Columns (Qiagen). 
Proteins were eluted using different concentrations of Imidazol as shown in Figures 29 A 
and B.  
 
 
Figure 29: Coomassie blue stained polyacrylamide gel. Elution with different concentrations of imidazol. Protein 
R4b (A) with expected size of 17.2 kDA and HEV2.1 (B) with expected size of 38 kDA. E: Elution steps. Selected 
fraction used in further experiments with R4b: elution 3 (E3).  
Purified protein R4b was tested in an immunoblot with one human and four swine 
anti-HEV positive sera known to be positive by ELISA. First a positive human serum was 
used. For swine, the four sera tested by a commercial ELISA (MP Diagnostic) were 
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positive, weak positive, strong positive, and negative. The sera were incubated overnight in 
a dilution of 1:50 (Fig. 30). In western blot the human serum showed a very discrete band 
which might indicate that it is reacting with our protein (Fig. 30). All swine sera were 
negative (data not shown).  
 
Figure 30: Immunoblot with R4b protein; human positive serum (1) and human negative serum (3) mAb anti-
ubiquitin (2). 
4.4 Cultivation of HEV 
So far there is no reliable cell culture system for propagation of HEV. Some cell lines 
such as human adenocarcinomic alveolar basal epithelial cells (A549) and human 
hepatoblastoma cells (PLC/PFR/5) have been reported to be permissive for HEV. However, 
no cytopathic effect could be associated with HEV propragation (Okamoto, 2011a; Tanaka 
et al., 2007). Thus, the growth of HEV in cells is measured by quantification of HEV RNA in 
the cells. A quantitative RT-PCR (qRT-PCR) assay was developed for this purpose.  
The RNA integrity, viral infectivity as well as the amount of viruses present in the 
domestic swine and wild boar samples (tested positive by RT-PCR in the first part of this 
thesis) was unknown. Therefore, for infection of cells a liver fragment from pigs 
experimentally infected with a genotype 3 HEV Dutch strain (DQ996399) was used 
(Bouwknegt et al., 2008); kindly provided by Prof Dr. Wim van der Poel.  
1 2 3 
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4.4.1 Realtime RT-PCR for HEV detection 
New primers and a probe were designed based on the Dutch strain DQ996399 
(Bouwknegt et al., 2008). The primers might amplify other HEV genotype 3 strains but, due 
to the high specificity, it is unlikely that the probe will bind with another viral strain. A 
quantitative PCR assay with the respective primers and probe was successfully validated 
for the detection and quantification of HEV in liver and in cell culture (Fig. 31 A and B). Cells 
were tested together with a housekeeping gene 18s. Accordingly, the Taqman assay was 
efficient to amplify the standard positive samples as evidenced by the fluorescence curve 
demonstrated in figure 31 A. The standard curve was generated using 10-serial fold 
dilutions. It is important to note the quantification does not represent the amount of viral 
RNA as there has been no reverse transcription control in the test.  
 
Figure 31: qRT-PCR validation based on serial diluted plasmid: (A) amplification of the standard positive and (B) 
standard curve. Slope =-3.316, intercept = 36.873, r = 0.996, E=100 %. 
4.4.2 Infection experiments 
A549 cells were infected with liver suspension from an experimentally infected pig 
(DQ996399). Infection was performed in the presence of different amounts of FCS in the 
medium (1, 2, 5 and 10 %). HEV RNA could be detected and quantified in cell supernatant 
samples and also in the cellular fraction. The amount of viral RNA in cell culture 
supernatants first decreased and then increased progressively from day 5 until day 15 in 
plates where 1 % FCS (Fig. 32) was used; however the amount of viruses detected was too 
low (2.79 x 102). No cytopathic effect (CPE) was detected and after the second passage 
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(after 28 days) it was not possible to detect HEV RNA either in cells or in supernatants. 
Using media with 2 % FCS higher and almost constant ct values were founded (Table 33). 
In the presence of concentration of 5% FCS HEV was detected only on days 1 and 2 after 
infection and the amount of virus estimate was low (higher ct values). 
Another infection experiment has been performed with shrew hepatocytes (kindly 
provided by Dr. Dieter Glebe, Institute of Medical Virology, JLU Giessen) and two distinct 
viruses: swine liver suspension (as was performed for the A549 cell line infection) and 
human positive serum (kindly provided by Dr. Christian Schüttler, Institute of Medical 
Virology JLU Giessen). Hepatocytes were kept for seven days. Culture supernatant was 
collected on days 1, 4 and 7 and at the end hepatocytes were harvested and analyzed by 
electron microscopy (EM). No HEV RNA was detected on days 1, 4 and 7 and no viral 
particles were observed by EM in hepatocytes on day 7 P.I. (data not shown). 
 
Figure 32: Increase of viral copies in the supernatant after infection with 100µl of liver suspension according to 
the day collected in the preliminary experiment.  
Table 33: Ct values of the infection with A549 cell line using different FCS concentrations. 
 FCS 1% 100 µl FCS 2 % 100µl 
Day 1 32.16 32.15 
Day 5 36.13 34.25 
Day 8 35.11 33.83 
Day 15 28.82 34.12 
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87 
 
5 Discussion 
5.1. Prevalence of hepatitis E virus (HEV) in swine and wild boar  
Domestic swine and wild boar have been reported as the major animal reservoir of 
HEV. Some retrospective studies suggest that HEV circulated in both domestic swine and 
wild boar for decades (Casas et al., 2009; Kaci et al., 2008).   
Within this study, HEV could be detected in 18 out of the 124 sera from wild boar, 
corresponding to a detection rate of 14.5 %. This implies that HEV is endemic in the wild 
boar population of western Hesse / Germany. The presence of HEV in wild boar has been 
shown in many countries including Germany (Kaci et al., 2008; Martelli et al., 2008). The 
high prevalence rate observed in the current study is comparable to those previously found 
in other parts of Germany (Adlhoch et al., 2009a; Schielke et al., 2009) and other European 
countries such as Spain (de Deus et al., 2008b) and Italy (Martelli et al., 2008). Lower 
prevalence rates were reported in France, the Netherlands and in a retrospective study for 
Germany (Kaba et al., 2009; Kaci et al., 2008; Rutjes et al., 2009).  
In contrast to the widespread occurrence in wild boar HEV was detected in only one 
out of 105 domestic swine analyzed. This rate is considerably lower than in other countries 
e.g. Brazil 9.3 % (dos Santos et al., 2009), Canada 34.4 % (Ward et al., 2008), China 47.9 
% (Geng et al., 2011), India 12.3 % (Arankalle et al., 2003), Japan 14.5 % (Tanaka et al., 
2004), United States 35.4 % (Huang et al., 2002) and also other European countries such 
as France 31.2 % (Kaba et al., 2009), Italy 29.9 % (Martelli et al., 2010), Spain 37.7 % (de 
Deus et al., 2007) and the Netherlands 22.0 % (van der Poel et al., 2001). Prevalence rates 
comparable to the current showed were reported China 0.8 % (Geng et al., 2010), Japan  
1.8 % (Sakano et al., 2009), Taiwan 1.3 % (Wu et al., 2000), India 2 % (Vivek and Kang, 
2011), Korea 1.9 % (Lee et al., 2009a), Indonesia 1 % (Utsumi et al., 2011), Bali 1% 
(Wibawa et al., 2004) and Congo 2.5 % (Kaba et al., 2010a).  
According to the data in this thesis HEV is apparently more widespread in the wild 
boar population than in domestic swine. There are however a number of technical factors 
that might have influenced the results. The difference in prevalence rates may be 
influenced by the kind of samples tested, like serum for wild boar and feces for domestic 
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swine. Experimental studies showed that HEV could be detected more frequently and for 
longer periods in feces in comparison to blood samples (Bouwknegt et al., 2009). Another 
factor is the presence of inhibitors of RT-PCR; we did neither test for inhibitors nor quantify 
the amount of HEV RNA. According to both field and experimental studies detection rates 
are correlated with age of animals. HEV RNA appears to be more easily detectable in 
domestic pigs up to six months of age in comparison to older animals (dos Santos et al., 
2009; Huang et al., 2002; Lee et al., 2009b). For animals in our study we have limited 
information about age.  
Social, behavioral and environmental differences between domestic swine and wild 
boar may play a role in viral transmission. Wild boar, as free-living opportunistic omnivores, 
may be exposed to constant re-infection. For domestic swine good hygiene conditions and 
the restriction of animal interaction probably influences the detection rates. It is remarkable 
that wild boar sera samples from Morocco were all negative for HEV RNA. A commercial 
ELISA gave no indication for antibodies against HEV (data not shown). Several outbreaks 
of HE in humans have been reported in different African countries such as Chad, Egypt, 
Kenya, Morocco, Somalia, Sudan and Uganda; the majority of HE viruses belonged to 
genotypes 1 or 2 not detected in animals up to now; infection was linked to contaminated 
food and water (Benjelloun et al., 1997; Teshale et al., 2010; Tsarev et al., 1999; van Cuyck 
et al., 2003). On the basis of our results one might assume that the wild boar population in 
Morocco is unlikely to be reservoir of HEV. Animals tested however came from an isolated 
population and we cannot infer whether the results are statistically significant for the 
general population. 
5.1.1. Phylogenetic analyses  
HEV is currently divided into four genotypes, GT 1 – GT 4. The subtype classification 
so far is not consensual. The currently most accepted classification of 24 HEV subtypes 
has been proposed by Lu and colleagues (Lu et al., 2006). They divided GT 3 into 10 
subtypes (a-j). The authors concluded that  the observed variability may be due to the 
extended host range found for GT 3 (Lu et al., 2006). Isolates found in this study clustered 
in two distinctly branches of GT 3 demonstrating the heterogeneity of HEV within the wild 
boar population.  
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Phylogenetic analyses based on a 241 b fragment of the capsid gene did neither 
provide reliable trees nor separation into subtypes. Phylogenetic analyses based on 
complete capsid gene sequences led to a higher reliability as shown by high bootstraps 
values and allowed a convincing separation in subtypes. Trying to fit our data into the 
existing system of subtyping we have faced problems: Analyses based on different regions 
of the genome used by Lu et al placed our isolates in different subtypes. We therefor 
concluded that the subtyping classification in proposed was inconsistent. The data in this 
study are limited since it was not possible to obtain complete capsid gene sequence for all 
isolates.  
The divergence observed within HEV sequences in the German wild boar population 
is remarkable. According to the analysis using the entire capsid gene, the two German 
isolates (FJ705359 and FJ998008) and the WB 1 isolate (KF303501) differ by 10.66 – 
13.54 %. This is a high divergence when compared to other subtypes. Even higher 
nucleotide divergence was found by comparison of WB1 (Rheingau-Taunus-Kreis) and WB 
69 (Hochtaunuskreis) (Figure 8), which were collected in neighbouring regions and showed 
a nucleotide divergence of 15.88 %. High heterogeneity plus distribution pattern indicates 
constant reinfection or immune evasion in the population. Constant re-infection with 
different strains together with the occurrence of viral recombination may explain such 
heterogeneity. 
Zoonotic transmission of HEV has been reported to be associated with the 
consumption of deer, swine and wild boar meat products (Colson et al., 2010; Tamada et 
al., 2004; Tei et al., 2003). The HEV genotype 3 strains detected in humans (AB074918, 
AB089824) and GiSw, WB 69 and WB 122 cluster together and cannot be genetically 
distinguished. The presence of similar HEV strains both in animals and humans suggests 
that HEV circulate between domestic animals, free living animals and humans. This 
highlights the zoonotic potential of HEV as indicated by an earlier epidemiological study 
with hepatitis E patients in Germany (Wichmann et al., 2008).  
5.1.2. Recombination of HEV 
Recombination has been reported for several viruses including influenza viruses, 
herpesviruses and vaccinia viruses (Burnet and Lind, 1951; Fenner and Comben, 1958; 
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Wildy, 1955). It is a common in positive sense RNA viruses like Corona- and Flavivirus (Bull 
et al., 2007; Coyne et al., 2006). Recombination is thought to drive viral evolution (Worobey 
and Holmes, 1999). Two mechanisms of RNA recombination have been proposed: 
Replicative template-switching and non-replicative breakage and rejoining (Becher and 
Tautz, 2011). 
Intra-genotype recombination within HEV genotype 1 has already been 
demonstrated with “China D” and “Nepal 15” isolates (van Cuyck et al., 2005). In addition 
inter-genotype recombination has been reported between members of genotypes 3 and 4 
(Fan, 2009). It has also been suggested that the single Mexican genotype 2 sequence is a 
product of inter-genotype recombination (Fan, 2009). Recombination may occur in a host 
infected with different HEV strains (van Cuyck et al., 2005). It is not clear whether 
recombination plays an important role in HEV virulence as shown for other positive strand 
RNA viruses (Mathijs et al., 2010). According to the results within this thesis recombination 
may have occurred and helps to explain the heterogeneity found in our samples, e.g. the 
subtype change of WB69 as well as difficulties in assigning other isolates to subtypes 
(Figures 10 and 12). However, it is important to note that the results presented here are 
limited as we were not able to sequence larger fragments of the viruses.  
5.2. Classification of HEV 
Viruses are classified in a universal taxonomic scheme developed and updated 
officially by the International Committee on Taxonomy of Viruses (ICTV). Currently the ICTV 
classifies viruses in orders, families, subfamilies, genera and species (King et al., 2011). 
Accordingly there is no general official definition for genotypes, genogroups, subgroups and 
subtypes and the classification criteria vary for each virus family.  
A proper classification of HEV and HEV-like viruses is important to understand the 
epidemiology of hepatitis E. It has been suggested that the clinical impact, including severe 
hepatic disease resulting in fulminant hepatic failure, might be related to the HEV genotype 
and subtype involved (Lewis et al., 2010). The lack of an unambiguous subtype 
classification scheme hinders a more detailed mapping of the molecular epidemiology of 
HEV. Moreover, the continuous increase of available sequence information makes it 
necessary to establish a generally accepted system for subtype classification. 
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In the first part of this thesis (detection of HEV in wild boar and domestic swine) it 
was not possible to obtain a clear definition of subtypes from all sequences found in 
domestic swine and wild boar. We therefore decided to perform a comprehensive analysis 
with all HEV complete sequences available. 
The phylogenetic analyses of HEV performed here led to inconsistencies at the 
subtype level and challenged the current system proposed by Lu and co-workers (2006). 
Subtypes had been established using different regions of the genome. However, this did 
not result in a statistically significant assortment of viruses in phylogenetic analyses, which 
was reflected by low bootstrap values. Bootstrap values of 95 % or greater are statistically 
significant and do support a clade. Values of at least 70 % may only be taken as an 
indication while values below 50 % should be rejected (Soltis and Soltis, 2003). In the main 
branches of the phylogenetic trees based on small fragments (Fig. 19 A, B and C) compiled 
in this work the bootstrap values for partial sequences were below 50 %. This explains the 
inconsistences we found in the subtype classification proposed by Lu et al. (2006). The 
latter shows low accuracy in defining subtypes, and parts of it could not be reproduced. 
Accordingly the currently most accepted subtype classification system (Lu et al., 2006) is 
not very precise and may not be suitable for clinical and epidemiological studies.  
In contrast, phylogenetic analyses based on complete HEV genomic sequences led 
to a consistent separation of established genotypes (GTs) and recently discovered isolates 
from rabbits, ferrets, rats and wild boar (Oliveira-Filho et al., 2013). High bootstrap values at 
the lower bifurcations demonstrated the robustness of the phylogenetic analysis. Topology 
of the tree and the high nucleotide distances observed between these HEV-like viruses and 
the established HEV genotypes suggest that the former should be placed in separate 
genera (Figures 21 und Table 30).  
Remarkable differences were observed with regard to heterogeneity within 
established HEV genotypes. The divergence within GT 1 is lower than within genotypes 3 
and 4. So far, GT 1 has only been found in humans. In contrast, viruses grouped in GT 3 
and 4 have been reported in humans and different animal species. The restricted host 
range may be connected to the lower divergence found within GT 1. On the other hand, a 
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limited amount of complete genomic sequences available for GT 1 in comparison to GT 3 
and GT 4 may have biased the analysis.  
Our approach significantly improved the robustness of the analyses as demonstrated 
by high bootstrap values (Fig. 21). The separation of GT 3 into three subgroups (3.1, 3.2 
and 3.3) is supported by the topology of phylogenetic trees based on both complete 
genomic and capsid gene sequences and the respective calculated nucleotide distances 
(Fig. 20, 21 and 22). The level of heterogeneity within GT 3 decreased  (to around 20 % as 
observed for GT 1 and GT 4) when GT 3.1, 3.2 and 3.3 were considered as separate 
subgroups (Figure 20). These three GT 3 subgroups can be further divided into several 
subtypes at a statistically significant level. However available epidemiological data do 
currently not support further subdivisions. The genotype 4 isolates clustered in several 
highly heterogeneous branches which precluded a further separation, however only few 
groups could be at statically significant levels. It is questionable whether the degree of 
divergence alone should serve for separation into subtypes. In our opinion a constant 
addition of new subtypes is not helpful as the separation is not supported by 
epidemiological data. Subtyping should be useful in analysis of sequences when serve as 
suitable variables for epidemiological and clinical studies or help to understand 
pathogenesis. Separation of genotypes 3 and 4 into subtypes using currently available data 
sets does not improve the understanding of HEV epidemiology and pathogenesis.  
The cutthroat trout virus (CTV) has been suggested to represent a member of the 
Hepeviridae family based on phylogenetic analyses (Batts et al., 2011). According to the 
deduced amino acid sequence of ORF1, CTV is 73-74 % distant from HEV and 84 – 86 % 
from Caliciviruses, Togaviruses and Picornaviruses. The genome organization of CTV 
differs from HEV, avian HEV (aHEV) and rodent HEV-like viruses with regard to the position 
of ORF3 (Batts et al., 2011). According to our analysis it is not clear whether CTV actually 
belongs to the Hepeviridae. Our approach was suitable for comparison of HEV with aHEV, 
ferret, rodent and bat HEV-like sequences, which exhibit a considerable degree of 
heterogeneity. This approach failed in the case of CTV. 
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5.3. Development of diagnostic tools  
The HEV capsid protein has been expressed using different systems like baculoviruses 
(Li et al., 1997), E. coli (Hu et al., 2008; Zhang et al., 2001a) and vaccinia virus (Carl et al., 
1994; Jiménez de Oya et al., 2012). Protein expression using bacterial-based systems has 
several advantages when compared to eukaryotic systems; it is relatively easy to handle, 
provides a rapid establishment of the expression system and allows the production of large 
amounts of protein (Cabrita et al., 2006; Stevens, 2000).  
The proteins HEV R4b (ORF 2: from aa 543 to 617) and HEV 2.1 (from aa 1 to 278) 
were expressed as fusion proteins in the pET 26b+ vector as shown by Western blots (WB) 
with antibodies against the his-tag and ubiquitin. For HEV 2.1 two specific bands occurred 
(Figure 28); the reason for this is not clear. The protein may form dimers (approx. 40 kDa). 
Oligomerization of HEV capsid protein fragments has been reported after expression in E. 
coli systems using as vectors pGEX20 (Zhang et al., 2001a) and pMD 18-T(Li et al., 
2009a). In addition it has been reported that the peptides were more immunogenic in WB in 
their dimeric than in monomeric form (Zhang et al., 2001a). 
Tests using the HEV R4b peptide have shown a discrete band with a human serum 
from patient tested HEV positive by ELISA (figure 30). Negative human sera shown non-
specific bands on western blot; the reason for that still has to be elucidated. Cross-reactive 
antibodies against the tag sequences of expressed proteins i.e. ubiquitin and his-tags may 
have been responsible. Anti-ubiquitin antibodies have been detected in human patients 
suffering from systemic lupus erythematous (Muller et al., 1988). No band on the expected 
size was observed when negative control sera from SPF swine were used. 
The polypeptides produced within this study may be the starting point for improvement 
of tools and diagnostic tests. Additional analysis of these polypeptides, different expression 
strategy (e.g. without tags or different vectors) as well as further studies with both human 
and swine sera should be carried out.  
5.4. Cultivation of HEV 
Replication of viruses in tissue culture cells represent a routine approach and has 
been used for decades in order to diagnose, identify and characterize viruses (Bryden et 
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al., 1977; Covalciuc et al., 1999; Dulbecco and Vogt, 1953; Eagle, 1955). Infection of cell 
lines is the most common method for viral propagation (Flint et al., 2009). The growth and 
propagation of viruses in cells can be monitored microscopically by occurrence of 
cytopathic effects, electron microscopy, immunological assays and detection of viral 
genomes (Flint et al., 2009). An efficient cell culture system for HEV would make it possible 
to study viral replication and to generate large amounts of virus for further studies. 
Several approaches have been followed in order to cultivate HEV, unfortunately 
without clear success. In two recent publications human adenocarcinomic alveolar basal 
epithelial cells (A549) and human hepatoblastoma cells (PLC/PFR/5) have been reported to 
be permissive for HEV (Takahashi et al., 2012; Tanaka et al., 2007). For this, 21 different 
cell lines were infected with a fecal suspension from a patient positive for HEV genotype 3; 
viral genome was followed by quantitative RT-PCR (Tanaka et al., 2007). Latter on the 
same system was successful for growth of HEV from feces and blood samples (Okamoto, 
2011a) and HEV from swine and wild boar commercial liver (Takahashi et al., 2012). 
Recently a three dimensional cell culture system based on PLC/PFR/5 cell line has been 
reported; viral propagation was measured by quantitative RT-PCR from the culture 
suspension and viral particles could be demonstrated within the cells by electron 
microscopy (Berto et al., 2013). 
In this work A549 cells were infected using different amounts of HEV and different 
concentrations of FCS. A slight increase in the HEV RNA levels measured by qRT-PCR in 
the supernatants was the only hint of a possible viral replication. The amount of viral RNA in 
cell culture supernatant however, was still lower than the amount used for the initial 
infection. In addition, no cytopathic effect (CPE) has been detected and after the second 
passage it has not been possible to detect HEV RNA in either cells or supernatants. 
Concerning the success and applicability of the cultivation system using A549 cell line our 
results are not in agreement with what has been demonstrated in previous studies 
(Okamoto, 2011b; Takahashi et al., 2012; Tanaka et al., 2007). The reason for that remains 
unclear. Different experimental conditions and different viral strain used in our experiment 
may have played a role.  
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Our data are preliminary with just a few experiments performed with one cell line. 
Accordingly the model using the A549 cell line is not suitable for use in further experiments, 
even though the A549 cell line seems to be somehow permissive to HEV infection.  
5.4.1. Infection of primary hepatocytes 
Infection of tree shrew (Tupaia belangeri) hepatocytes with Hepatitis B virus (HBV) 
has been reported as a good in vitro model (Glebe et al., 2003). According to our 
knowledge no HEV propagation systems has been developed using tree shrew 
hepatocytes. Hence, we wanted to determine whether the shrew hepatocytes are suitable 
for HEV infection. For the established HEV cultivation systems using cell lines, 12 days post 
infection in the 2D system and 24 days after infection in the 3D system were necessary to 
evidence infection (Berto et al., 2013; Tanaka et al., 2007). 
In our study no signs of replication as judged by EM and qRT-PCR have been found. 
The cells could not be kept for more than seven days either due to inadequate maintenance 
conditions or due to natural limitations. Infection for longer periods has been required in 
order to demonstrate the HEV infection in both 2D and 3D systems. Thus, we cannot draw 
any conclusions regarding to permissibility of tree shrew hepatocytes to HEV infection. 
Further studies should be carried out with shrew hepatocytes using better maintenance 
conditions. 
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6 Summary 
Hepatitis E is an emerging zoonotic disease distributed worldwide. The causative agent 
Hepatitis E virus (HEV) is also present in animals such as swine, wild boar, deer, rabbits and 
rodents, however no clinical disease has been associated with HEV in animals. The limitations 
concerning diagnosis and the lack of clinical and epidemiological information about HEV in 
different animal populations make it difficult to assess the risk for the human population. Due 
to the lack of an efficient cell culture system, little knowledge is currently available about 
replication mechanisms, pathogenesis and biology of HEV. Thus, the aims of this study were 
to detect HEV in different animal populations, to study the genetic variability of HEV, to 
express the capsid protein for use in diagnostic test and to cultivate HEV in primary cells and 
cell lines.  
This study indicates that HEV is present in both wild boar and domestic swine 
populations in Germany. A high genetic heterogeneity has been found among the wild boar 
viruses. All HEV isolates from animals described in this study are closely related to human 
isolates indicating a potential zoonotic risk regarding the consumption of meat products 
especially from wild boar.  
Extensive phylogenetic analyses were performed in order to study the genetic variability 
of HEV and to evaluate the classification at subtype and genotype level. Phylogenetic 
analyses on the basis of complete genomic as well as whole capsid sequences were shown to 
be adequate for defining HEV genotypes. The results of the phylogenetic analyses suggest 
modification in the current taxonomy of genotype 3 and to refine the established system for 
typing of HEV. In addition a classification for hepeviruses recently isolated from bats, ferrets, 
rats and wild boar is suggested. 
 Parts of the HEV capsid protein (ORF 2: aa 1 to 278 and aa 543 to 617) were 
expressed as fusion proteins which can be used to develop test systems. Furthermore, a qRT-
PCR assay was developed. Numerous approaches were performed to cultivate HEV in cell 
lines and shrew hepatocytes; however, virus propagation could not be shown.
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7 Zusammenfassung 
Hepatitis E ist eine zoonotische Erkrankung mit weltweiter Verbreitung und 
zunehmender Bedeutung. Der Erreger, das Hepatitis E Virus (HEV), kommt auch bei Tieren 
wie Hausschweinen, Wildschweinen, Hirschen, Hasen und Nagetieren vor. Bisher wurden bei 
Tieren keine Erkrankungen durch HEV beschrieben. Die Einschränkungen bezüglich  
Diagnostik sowie das Fehlen von klinischen und epidemiologischen Daten über HEV bei 
verschiedenen Tierarten erlaubt es nicht, die Bedrohung für den Menschen abschließend zu 
beurteilen. 
Infolge des Fehlens eines effizienten Zellkultursystems ist nur wenig über die 
Replikation, die Pathogenese und die Biologie von HEV bekannt. Ziele dieser Arbeit waren, 
HEV in verschiedenen Tierpopulationen zu detektieren, die genetische Variabilität von HEV zu 
untersuchen, das Kapsidprotein für den Einsatz in Testsystemen zu exprimieren sowie HEV in 
primären Zellen bzw. in Zelllinien zu vermehren. 
Die vorliegende Studie zeigt, dass HEV in Wildschweinen und Hausschweinen 
vorkommt. Eine hohe genetische Heterogenität wurde bei den Viren aus Wildschweinen 
gefunden. Alle HEV Isolate von Tieren, die hier beschrieben werden, sind nahe mit humanen 
Isolaten verwandt, was auf die Gefahr einer zoonotischen Übertragung durch den Verzehr von 
Fleischprodukten insbesondere von Wildschweinen hinweist. 
Umfangreiche phylogenetische Analysen wurden durchgeführt, um die genetische 
Variabilität von HEV zu untersuchen und die bestehende Klassifizierung auf Subtyp- und 
Genotyp-Ebene zu evaluieren. Phylogenetische Analysen auf der Basis des kompletten 
Genoms und des gesamten Kapsidproteingens waren geeignet, um HEV Genotypen zu 
definieren. Die Ergebnisse der phylogenetischen Analysen legen nahe, dass die gegenwärtige 
Taxonomie von HEV modifiziert und das etablierte Einstufungssystem verfeinert werden 
sollten. Zusätzlich wird eine Klassifizierung von Hepeviren, die vor kurzem aus Fledermäusen, 
Frettchen und Wildschweinen isoliert wurden, angeregt. 
Teile des Kapsidproteins von HEV (ORF 2: AA 1 bis 278 und AA 543 bis 617) wurden 
als Fusionsproteine exprimiert und können zur Entwicklung weitergehender Testsysteme 
verwendet werden. Darüberhinaus wurde ein qRT-PCR Test für HEV entwickelt. Zahlreiche 
Ansätze zur Kultivierung von HEV in der Zelllinie A549 sowie in Hepatozyten von Spitzmäusen 
wurden durchgeführt; Virusvermehrung konnte jedoch nicht nachgewiesen werden. 
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